Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CONTRACEPTIVE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CONTRACEPTIVE MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CONTRACEPTIVE MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 EPIDEMIOLOGY
4.1 CONTRACEPTIVE PREVALENCE BY REGION AND GENDER
4.2 USAGE RATE AND USER DEMOGRAPHICS
4.3 UNMET NEED FOR FAMILY PLANNING
4.4 ADHERENCE TO CONTRACEPTIVE METHODS
4.5 CONTRACEPTIVE FAILURE AND SWITCHING RATE
4.6 PATIENT TREATMENT SUCCESS RATES
5 REGULATORY FRAMEWORK
5.1 REGULATORY APPROVAL PROCESS
5.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL
5.3 REGULATORY APPROVAL PATHWAYS
5.4 LICENSING AND REGISTRATION
5.5 POST-MARKETING SURVEILLANCE
5.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6 PIPELINE ANALYSIS
6.1 CLINICAL TRIALS AND PHASE ANALYSIS
6.2 CONTRACEPTIVE DRUG AND DEVICE PIPELINE
6.3 PHASE III CANDIDATES
6.4 PHASE II CANDIDATES
6.5 PHASE I CANDIDATES
6.6 OTHERS (PRE-CLINICAL AND RESEARCH)
7 MARKETED CONTRACEPTIVE PRODUCT ANALYSIS
7.1 CONTRACEPTIVE DRUGS AND DEVICES
7.1.1 BRAND NAME
7.1.2 GENERIC NAME
7.2 THERAPEUTIC INDICATION OR USE
7.3 PHARMACOLOGICAL/MECHANICAL CLASS
7.4 PRIMARY CONTRACEPTIVE INDICATION
7.5 MARKET STATUS
7.6 MEDICATION / DEVICE TYPE
7.7 DOSAGE FORM
7.8 DOSAGES AVAILABILITY / SIZES
7.9 PACKAGING TYPE
7.1 ROUTE/MODE OF ADMINISTRATION
7.11 DOSING FREQUENCY
7.12 PRODUCT INSIGHT
7.13 OVERVIEW OF REGULATORY MILESTONES, SAFETY & EFFICACY DATA, MARKET EXCLUSIVITY
7.13.1 FORECAST MARKET OUTLOOK
7.13.2 CROSS COMPETITION
7.13.3 THERAPEUTIC & TECHNOLOGY PORTFOLIO
7.13.4 CURRENT DEVELOPMENT SCENARIO
8 MARKET ACCESS
8.1 10-YEAR MARKET FORECAST
8.2 CLINICAL TRIAL RECENT UPDATES
8.3 ANNUAL NEW APPROVED PRODUCTS
8.4 MAJOR MANUFACTURERS AND DEALS
8.5 MAJOR PRODUCT UPTAKE
8.6 CURRENT FAMILY PLANNING AND CONTRACEPTIVE PRACTICES
8.7 IMPACT OF UPCOMING INNOVATIONS
9 R & D ANALYSIS
9.1 COMPARATIVE ANALYSIS
9.2 PRODUCT DEVELOPMENT LANDSCAPE
9.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
9.4 TECHNOLOGICAL/TREATMENT ASSESSMENT
9.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
10 MARKET OVERVIEW
10.1 DRIVERS
10.1.1 RISING FOCUS ON PREVENTING UNPLANNED PREGNANCY AND FAMILY PLANNING
10.1.2 GOVERNMENT INITIATIVES AND FUNDING
10.1.3 LONGER LICENSED DURATIONS LIFTING DEMAND FOR LONG-ACTING REVERSIBLE METHODS
10.1.4 PHARMACY AND OVER-THE-COUNTER ACCESS REMOVING THE PRESCRIPTION STEP
10.1.5 NEW PRODUCT APPROVALS WIDENING THE METHOD MIX BEYOND THE PILL AND THE HORMONAL IUD
10.2 RESTRAINTS
10.2.1 CONTRACEPTIVE SIDE EFFECTS
10.2.2 SOCIAL OR RELIGIOUS HESITATION, STIGMA
10.2.3 CONTRACTION OF DONOR FUNDING AFTER THE 2025 U.S. FOREIGN-AID CUTS AND THE CLOSURE OF USAID
10.2.4 GENERIC PRICE EROSION AND REIMBURSEMENT LIMITS ON OFF-PATENT HORMONAL BRANDS
10.3 OPPORTUNITIES
10.3.1 ADVANCES IN NOVEL CONTRACEPTIVE TECHNOLOGIES (LARC, NON-HORMONAL)
10.3.2 GROWTH IN DEVELOPING REGIONS WITH LOW PENETRATION
10.3.3 SELF-INJECTION AND OVER-THE-COUNTER PILLS MOVING CONTRACEPTION OUT OF THE CLINIC
10.3.4 A MALE CONTRACEPTION PIPELINE APPROACHING ITS FIRST PIVOTAL TRIAL
10.4 CHALLENGES
10.4.1 LONG-TERM SAFETY PERCEPTION ISSUES
10.4.2 SHIFT TOWARD LONG-ACTING AND MALE CONTRACEPTIVE OPTIONS
10.4.3 DMPA MENINGIOMA LITIGATION AND LABEL CHANGES ON INJECTABLES
10.4.4 FERTILITY DECLINE SHRINKING THE USER BASE IN AGEING MARKETS
10.5 EMERGING TRENDS IN THE INDUSTRY
10.5.1 TELEHEALTH PLATFORMS AND DIRECT-TO-CONSUMER SITES TAKING OVER THE PILL REFILL
10.5.2 SELF-INJECTABLE DMPA MOVING THE INJECTABLE OUT OF THE CLINIC
10.5.3 NON-HORMONAL AND MALE METHODS ADVANCING THROUGH CLINICAL DEVELOPMENT
10.5.4 WOMEN'S HEALTH PORTFOLIOS CONSOLIDATING INTO FEWER, LARGER OWNERS
10.5.5 DROSPIRENONE BECOMING THE PROGESTIN OF CHOICE IN NEW ORAL CONTRACEPTIVES
10.6 IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES
10.7 PORTER'S FIVE FORCES ANALYSIS
10.8 PESTEL ANALYSIS
11 PATENT ANALYSIS
11.1 PATENT NUMBER AND EXPIRY
11.2 COUNTRY LEVEL APPROVAL
11.3 LIST OF PRODUCTS REACHING EXPIRY IN NEXT 3 YEARS
11.4 PRODUCTS PATENTED IN SPECIFIC COUNTRIES
12 COMPANY EVALUATION QUADRANT
13 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2018–2033 (USD MILLION)
13.1 OVERVIEW
13.2 CONTRACEPTIVE DRUGS
13.2.1 ORAL CONTRACEPTIVES
13.2.1.1 COMBINED ORAL CONTRACEPTIVES
13.2.1.1.1 MONOPHASIC PILLS
13.2.1.1.2 21-DAY REGIMEN
13.2.1.1.3 24/4 REGIMEN
13.2.1.1.4 EXTENDED / CONTINUOUS REGIMEN
13.2.1.1.5 BIPHASIC PILLS
13.2.1.1.6 TRIPHASIC PILLS
13.2.1.2 PROGESTIN-ONLY PILLS
13.2.1.2.1 TRADITIONAL PROGESTIN-ONLY PILLS
13.2.1.2.2 DROSPIRENONE-BASED PILLS
13.2.1.3 EMERGENCY CONTRACEPTIVE PILLS
13.2.1.3.1 LEVONORGESTREL-BASED
13.2.1.3.2 SINGLE-DOSE REGIMEN
13.2.1.3.3 SPLIT-DOSE REGIMEN
13.2.1.3.4 ULIPRISTAL ACETATE-BASED
13.2.2 INJECTABLE CONTRACEPTIVES
13.2.2.1 PROGESTIN-ONLY INJECTABLES
13.2.2.1.1 DEPOT MEDROXYPROGESTERONE ACETATE (DMPA)
13.2.2.1.2 INTRAMUSCULAR DMPA
13.2.2.1.3 SUBCUTANEOUS DMPA
13.2.2.1.4 NORETHISTERONE ENANTHATE (NET-EN)
13.2.2.2 COMBINED INJECTABLE CONTRACEPTIVES
13.2.2.2.1 MONTHLY COMBINED INJECTABLES
13.2.3 TRANSDERMAL CONTRACEPTIVE PATCHES
13.2.3.1 COMBINED HORMONAL PATCHES
13.2.3.1.1 ETHINYL ESTRADIOL + NORELGESTROMIN
13.2.3.1.2 ETHINYL ESTRADIOL + LEVONORGESTREL
13.2.4 VAGINAL HORMONAL CONTRACEPTIVES
13.2.4.1 MONTHLY VAGINAL RINGS
13.2.4.1.1 ETONOGESTREL + ETHINYL ESTRADIOL RINGS
13.2.4.2 EXTENDED-USE VAGINAL RINGS
13.2.4.2.1 SEGESTERONE ACETATE + ETHINYL ESTRADIOL RINGS
13.3 CONTRACEPTIVE DEVICES
13.3.1 CONDOMS
13.3.1.1 MALE CONDOMS
13.3.1.1.1 LATEX CONDOMS
13.3.1.1.2 LUBRICATED LATEX CONDOMS
13.3.1.1.3 NON-LUBRICATED LATEX CONDOMS
13.3.1.1.4 NON-LATEX CONDOMS
13.3.1.1.5 POLYURETHANE MALE CONDOMS
13.3.1.1.6 POLYISOPRENE MALE CONDOMS
13.3.1.1.7 OTHER SYNTHETIC MATERIAL CONDOMS
13.3.1.2 FEMALE / INTERNAL CONDOMS
13.3.1.2.1 NITRILE CONDOMS
13.3.1.2.2 POLYURETHANE FEMALE CONDOMS
13.3.1.2.3 OTHER MATERIAL FEMALE CONDOMS
13.3.2 INTRAUTERINE DEVICES (IUDS)
13.3.2.1 COPPER IUDS
13.3.2.1.1 COPPER T-SHAPED IUDS
13.3.2.1.2 CUT 380A
13.3.2.1.3 CUT 375
13.3.2.1.4 OTHER COPPER IUDS
13.3.2.1.5 MULTILOAD / HORSESHOE-TYPE
13.3.2.2 HORMONAL IUDS
13.3.2.2.1 LEVONORGESTREL-RELEASING IUDS
13.3.2.2.2 52 MG LNG-IUDS
13.3.2.2.3 19.5 MG LNG-IUDS
13.3.2.2.4 13.5 MG LNG-IUDS
13.3.3 SUBDERMAL CONTRACEPTIVE IMPLANTS
13.3.3.1 SINGLE-ROD IMPLANTS
13.3.3.1.1 ETONOGESTREL IMPLANTS
13.3.3.2 DOUBLE-ROD IMPLANTS
13.3.3.2.1 LEVONORGESTREL IMPLANTS
13.3.4 OTHER BARRIER CONTRACEPTIVE DEVICES
13.3.4.1 DIAPHRAGMS
13.3.4.1.1 TRADITIONAL DIAPHRAGMS
13.3.4.1.2 ONE-SIZE DIAPHRAGMS
13.3.4.2 CERVICAL CAPS
13.3.4.3 CONTRACEPTIVE SPONGES
13.3.5 FEMALE STERILIZATION DEVICES
13.3.5.1 TUBAL OCCLUSION DEVICES
13.3.5.2 OTHER STERILIZATION DEVICES
13.4 CONTRACEPTIVE SPERMICIDES & ADJUNCT PRODUCTS
13.4.1 SPERMICIDAL GELS
13.4.1.1 NONOXYNOL-9-BASED GELS
13.4.1.2 OTHER SPERMICIDAL GELS
13.4.2 SPERMICIDAL FOAMS
13.4.2.1 AEROSOL FOAMS
13.4.2.2 NON-AEROSOL FOAMS
13.4.3 SPERMICIDAL FILMS
13.4.3.1 VAGINAL CONTRACEPTIVE FILMS
13.4.4 SPERMICIDAL SUPPOSITORIES
13.4.4.1 VAGINAL SUPPOSITORIES
13.4.5 VAGINAL PH MODULATORS
13.4.5.1 LACTIC ACID-BASED
13.4.5.2 CITRIC ACID / POTASSIUM BITARTRATE-BASED
13.4.5.3 OTHER NON-HORMONAL PH MODULATORS
14 GLOBAL CONTRACEPTIVE MARKET, BY HORMONAL COMPOSITION, 2018–2033 (USD MILLION)
14.1 OVERVIEW
14.2 ESTROGEN + PROGESTIN COMBINATION CONTRACEPTIVES
14.2.1 COMBINED ORAL PILLS
14.2.2 COMBINED TRANSDERMAL PATCHES
14.2.3 COMBINED VAGINAL RINGS
14.2.4 COMBINED INJECTABLES
14.3 PROGESTIN-ONLY CONTRACEPTIVES
14.3.1 PROGESTIN-ONLY ORAL PILLS
14.3.2 PROGESTIN-ONLY INJECTABLES (HORMONAL)
14.3.3 PROGESTIN-ONLY SUBDERMAL IMPLANTS
14.3.4 PROGESTIN-ONLY HORMONAL IUDS
14.4 NON-HORMONAL CONTRACEPTIVES
14.4.1 NON-HORMONAL COPPER IUDS
14.4.2 NON-HORMONAL CONDOMS
14.4.3 NON-HORMONAL DIAPHRAGMS
14.4.4 NON-HORMONAL CERVICAL CAPS
14.4.5 NON-HORMONAL SPERMICIDES
14.4.6 NON-HORMONAL VAGINAL PH MODULATORS
14.4.7 OTHER NON-HORMONAL CONTRACEPTIVES
14.5 OTHER HORMONAL CONTRACEPTIVES
15 GLOBAL CONTRACEPTIVE MARKET, BY DURATION OF ACTION, 2018–2033 (USD MILLION)
15.1 OVERVIEW
15.2 SHORT-ACTING REVERSIBLE CONTRACEPTIVES
15.2.1 SHORT-ACTING ORAL CONTRACEPTIVE PILLS
15.2.2 SHORT-ACTING CONDOMS
15.2.3 SHORT-ACTING PATCHES
15.2.4 SHORT-ACTING VAGINAL RINGS
15.2.5 SHORT-ACTING SPERMICIDES
15.2.6 OTHER SHORT-ACTING METHODS
15.3 INTERMEDIATE-ACTING CONTRACEPTIVES
15.3.1 INTERMEDIATE-ACTING INJECTABLES
15.4 LONG-ACTING REVERSIBLE CONTRACEPTIVES (LARC)
15.4.1 LARC INTRAUTERINE DEVICES
15.4.1.1 LARC COPPER IUDS
15.4.1.2 LARC HORMONAL IUDS
15.4.2 LARC SUBDERMAL IMPLANTS
15.5 PERMANENT CONTRACEPTION
15.5.1 PERMANENT FEMALE STERILIZATION DEVICES
16 GLOBAL CONTRACEPTIVE MARKET, BY ROUTE OF ADMINISTRATION, 2018–2033 (USD MILLION)
16.1 OVERVIEW
16.2 ORAL
16.2.1 DAILY ORAL CONTRACEPTIVES
16.2.2 EMERGENCY ORAL CONTRACEPTIVES
16.3 INJECTABLE
16.3.1 INTRAMUSCULAR
16.3.2 SUBCUTANEOUS
16.4 TRANSDERMAL
16.4.1 TRANSDERMAL ROUTE PATCHES
16.5 VAGINAL
16.5.1 VAGINAL ROUTE RINGS
16.5.2 VAGINAL ROUTE SPERMICIDES
16.5.3 VAGINAL ROUTE PH MODULATORS
16.5.4 VAGINAL ROUTE DIAPHRAGMS
16.5.5 VAGINAL ROUTE CERVICAL CAPS
16.5.6 OTHER VAGINAL METHODS
16.6 INTRAUTERINE
16.6.1 INTRAUTERINE COPPER IUDS
16.6.2 INTRAUTERINE HORMONAL IUDS
16.7 SUBDERMAL
16.7.1 SUBDERMAL ROUTE IMPLANTS
16.8 EXTERNAL APPLICATION
16.8.1 EXTERNAL MALE CONDOMS
16.8.2 EXTERNAL FEMALE CONDOMS
16.9 OTHER ROUTES
17 GLOBAL CONTRACEPTIVE MARKET, BY GENDER, 2018–2033 (USD MILLION)
17.1 OVERVIEW
17.2 FEMALE CONTRACEPTIVES
17.2.1 FEMALE ORAL CONTRACEPTIVES
17.2.2 FEMALE INJECTABLES
17.2.3 FEMALE PATCHES
17.2.4 FEMALE VAGINAL RINGS
17.2.5 FEMALE IUDS
17.2.6 FEMALE IMPLANTS
17.2.7 FEMALE DIAPHRAGMS
17.2.8 FEMALE CONDOMS
17.2.9 OTHER FEMALE CONTRACEPTIVES
17.3 MALE CONTRACEPTIVES
17.3.1 MALE CONDOMS (MALE USERS)
18 GLOBAL CONTRACEPTIVE MARKET, BY PRESCRIPTION STATUS, 2018–2033 (USD MILLION)
18.1 OVERVIEW
18.2 PRESCRIPTION CONTRACEPTIVES
18.2.1 PRESCRIPTION ORAL CONTRACEPTIVES
18.2.2 PRESCRIPTION INJECTABLE CONTRACEPTIVES
18.2.3 PRESCRIPTION PATCHES
18.2.4 PRESCRIPTION VAGINAL RINGS
18.2.5 PRESCRIPTION IUDS
18.2.6 PRESCRIPTION IMPLANTS
18.2.7 OTHER PRESCRIPTION CONTRACEPTIVES
18.3 OVER-THE-COUNTER (OTC) CONTRACEPTIVES
18.3.1 OTC CONDOMS
18.3.2 OTC SPERMICIDES
18.3.3 SELECTED EMERGENCY CONTRACEPTIVE PILLS
18.3.4 OTC VAGINAL PH MODULATORS
18.3.5 OTHER OTC CONTRACEPTIVES
19 GLOBAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2018–2033 (USD MILLION)
19.1 OVERVIEW
19.2 ADOLESCENTS (10-19 YEARS)
19.3 YOUNG ADULTS (20-29 YEARS)
19.4 ADULTS (30-44 YEARS)
19.5 OLDER REPRODUCTIVE-AGE POPULATION (45-49 YEARS)
20 GLOBAL CONTRACEPTIVE MARKET, BY END USER, 2018–2033 (USD MILLION)
20.1 OVERVIEW
20.2 HOSPITALS
20.2.1 PUBLIC HOSPITALS
20.2.2 PRIVATE HOSPITALS
20.3 GYNECOLOGY & OBSTETRIC CLINICS
20.3.1 GENERAL GYNECOLOGY CLINICS
20.3.2 REPRODUCTIVE HEALTH CLINICS
20.4 FAMILY PLANNING CENTERS
20.4.1 PUBLIC FAMILY PLANNING CENTERS
20.4.2 PRIVATE / NGO-OPERATED FAMILY PLANNING CENTERS
20.5 COMMUNITY HEALTH CENTERS
20.6 INDIVIDUAL / HOME USERS
21 GLOBAL CONTRACEPTIVE MARKET, BY DISTRIBUTION CHANNEL, 2018–2033 (USD MILLION)
21.1 OVERVIEW
21.2 HOSPITAL PHARMACIES
21.3 RETAIL PHARMACIES & DRUG STORES
21.4 ONLINE PHARMACIES
21.4.1 PHARMACY WEBSITES
21.4.2 E-COMMERCE PLATFORMS
21.5 DIRECT / INSTITUTIONAL SALES
21.5.1 DIRECT SALES TO HOSPITALS & CLINICS
21.5.2 GOVERNMENT PROCUREMENT
21.5.3 NGO / HUMANITARIAN PROCUREMENT
22 GLOBAL CONTRACEPTIVE MARKET, BY REGION, 2018–2033 (USD MILLION)
22.1 OVERVIEW
22.2 GLOBAL
22.2.1 NORTH AMERICA
22.2.1.1 U.S.
22.2.1.2 CANADA
22.2.1.3 MEXICO
22.2.2 EUROPE
22.2.2.1 GERMANY
22.2.2.2 U.K.
22.2.2.3 ITALY
22.2.2.4 FRANCE
22.2.2.5 SPAIN
22.2.2.6 SWITZERLAND
22.2.2.7 RUSSIA
22.2.2.8 TURKEY
22.2.2.9 BELGIUM
22.2.2.10 NETHERLANDS
22.2.2.11 DENMARK
22.2.2.12 NORWAY
22.2.2.13 FINLAND
22.2.2.14 SWEDEN
22.2.2.15 REST OF EUROPE
22.2.3 ASIA PACIFIC
22.2.3.1 JAPAN
22.2.3.2 CHINA
22.2.3.3 SOUTH KOREA
22.2.3.4 INDIA
22.2.3.5 SINGAPORE
22.2.3.6 THAILAND
22.2.3.7 INDONESIA
22.2.3.8 MALAYSIA
22.2.3.9 PHILIPPINES
22.2.3.10 AUSTRALIA
22.2.3.11 NEW ZEALAND
22.2.3.12 HONG KONG
22.2.3.13 TAIWAN
22.2.3.14 REST OF ASIA-PACIFIC
22.2.4 SOUTH AMERICA
22.2.4.1 ARGENTINA
22.2.4.2 BOLIVIA
22.2.4.3 BRAZIL
22.2.4.4 CHILE
22.2.4.5 COLOMBIA
22.2.4.6 ECUADOR
22.2.4.7 PARAGUAY
22.2.4.8 PERU
22.2.4.9 URUGUAY
22.2.4.10 VENEZUELA
22.2.4.11 REST OF SOUTH AMERICA
22.2.5 MIDDLE EAST AND AFRICA
22.2.5.1 SOUTH AFRICA
22.2.5.2 EGYPT
22.2.5.3 SAUDI ARABIA
22.2.5.4 UNITED ARAB EMIRATES
22.2.5.5 ISRAEL
22.2.5.6 BAHRAIN
22.2.5.7 KUWAIT
22.2.5.8 OMAN
22.2.5.9 QATAR
22.2.5.10 REST OF MIDDLE EAST & AFRICA
23 GLOBAL CONTRACEPTIVE MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS
23.2 MERGERS & ACQUISITIONS
23.3 NEW PRODUCT DEVELOPMENT & APPROVALS
23.4 EXPANSIONS
23.5 REGULATORY CHANGES
23.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 GLOBAL CONTRACEPTIVE MARKET, SWOT AND DBMR ANALYSIS
24.1 SWOT ANALYSIS
25 GLOBAL CONTRACEPTIVE MARKET, COMPANY PROFILES
25.1 GLOBAL PHARMACEUTICAL AND WOMEN'S HEALTH COMPANIES
25.1.1 BAYER AG
25.1.1.1 COMPANY OVERVIEW
25.1.1.2 REVENUE ANALYSIS
25.1.1.3 GEOGRAPHIC PRESENCE
25.1.1.4 COLLABORATION
25.1.1.5 PRODUCTION CAPACITY EXPANSION
25.1.1.6 INNOVATIONS
25.1.1.7 EVENTS
25.1.1.8 OTHERS
25.1.1.9 PRODUCT PORTFOLIO
25.1.1.10 RECENT DEVELOPMENTS
25.1.1.11 RECENT NEWS
25.1.2 ORGANON & CO.
25.1.2.1 COMPANY OVERVIEW
25.1.2.2 REVENUE ANALYSIS
25.1.2.3 GEOGRAPHIC PRESENCE
25.1.2.4 MAJOR DEALS
25.1.2.5 M&A
25.1.2.6 COLLABORATION
25.1.2.7 PRODUCT ACQUISITION
25.1.2.8 INNOVATIONS
25.1.2.9 EVENTS
25.1.2.10 OTHERS
25.1.2.11 PRODUCT PORTFOLIO
25.1.2.12 RECENT DEVELOPMENTS
25.1.2.13 RECENT NEWS
25.1.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
25.1.3.1 COMPANY OVERVIEW
25.1.3.2 REVENUE ANALYSIS
25.1.3.3 GEOGRAPHIC PRESENCE
25.1.3.4 M&A
25.1.3.5 OTHERS
25.1.3.6 PRODUCT PORTFOLIO
25.1.3.7 RECENT DEVELOPMENTS
25.1.3.8 RECENT NEWS
25.1.4 PFIZER INC.
25.1.4.1 COMPANY OVERVIEW
25.1.4.2 REVENUE ANALYSIS
25.1.4.3 GEOGRAPHIC PRESENCE
25.1.4.4 MAJOR DEALS
25.1.4.5 COLLABORATION
25.1.4.6 PRODUCTION CAPACITY EXPANSION
25.1.4.7 OTHERS
25.1.4.8 PRODUCT PORTFOLIO
25.1.4.9 RECENT DEVELOPMENTS
25.1.4.10 RECENT NEWS
25.1.5 GEDEON RICHTER PLC.
25.1.5.1 COMPANY OVERVIEW
25.1.5.2 REVENUE ANALYSIS
25.1.5.3 GEOGRAPHIC PRESENCE
25.1.5.4 MAJOR DEALS
25.1.5.5 M&A
25.1.5.6 COLLABORATION
25.1.5.7 PRODUCT ACQUISITION
25.1.5.8 INNOVATIONS
25.1.5.9 PRODUCT LAUNCHES
25.1.5.10 EVENTS
25.1.5.11 OTHERS
25.1.5.12 PRODUCT PORTFOLIO
25.1.5.13 RECENT DEVELOPMENTS
25.1.5.14 RECENT NEWS
25.1.6 VIATRIS INC.
25.1.6.1 COMPANY OVERVIEW
25.1.6.2 REVENUE ANALYSIS
25.1.6.3 GEOGRAPHIC PRESENCE
25.1.6.4 MAJOR DEALS
25.1.6.5 M&A
25.1.6.6 INNOVATIONS
25.1.6.7 PRODUCT LAUNCHES
25.1.6.8 CONFERENCES
25.1.6.9 OTHERS
25.1.6.10 PRODUCT PORTFOLIO
25.1.6.11 RECENT DEVELOPMENTS
25.1.6.12 RECENT NEWS
25.1.7 SUN PHARMACEUTICAL INDUSTRIES LTD.
25.1.7.1 COMPANY OVERVIEW
25.1.7.2 REVENUE ANALYSIS
25.1.7.3 GEOGRAPHIC PRESENCE
25.1.7.4 MAJOR DEALS
25.1.7.5 M&A
25.1.7.6 INNOVATIONS
25.1.7.7 EVENTS
25.1.7.8 OTHERS
25.1.7.9 PRODUCT PORTFOLIO
25.1.7.10 RECENT DEVELOPMENTS
25.1.7.11 RECENT NEWS
25.1.8 LUPIN
25.1.8.1 COMPANY OVERVIEW
25.1.8.2 REVENUE ANALYSIS
25.1.8.3 GEOGRAPHIC PRESENCE
25.1.8.4 MAJOR DEALS
25.1.8.5 INNOVATIONS
25.1.8.6 PRODUCT LAUNCHES
25.1.8.7 EVENTS
25.1.8.8 OTHERS
25.1.8.9 PRODUCT PORTFOLIO
25.1.8.10 RECENT DEVELOPMENTS
25.1.8.11 RECENT NEWS
25.1.9 GLENMARK PHARMACEUTICALS
25.1.9.1 COMPANY OVERVIEW
25.1.9.2 REVENUE ANALYSIS
25.1.9.3 GEOGRAPHIC PRESENCE
25.1.9.4 MAJOR DEALS
25.1.9.5 M&A
25.1.9.6 INNOVATIONS
25.1.9.7 PRODUCT LAUNCHES
25.1.9.8 EVENTS
25.1.9.9 OTHERS
25.1.9.10 PRODUCT PORTFOLIO
25.1.9.11 RECENT DEVELOPMENTS
25.1.9.12 RECENT NEWS
25.1.10 CIPLA
25.1.10.1 COMPANY OVERVIEW
25.1.10.2 REVENUE ANALYSIS
25.1.10.3 GEOGRAPHIC PRESENCE
25.1.10.4 COLLABORATION
25.1.10.5 INNOVATIONS
25.1.10.6 EVENTS
25.1.10.7 OTHERS
25.1.10.8 PRODUCT PORTFOLIO
25.1.10.9 RECENT DEVELOPMENTS
25.1.10.10 RECENT NEWS
25.1.11 APOTEX INC.
25.1.11.1 COMPANY OVERVIEW
25.1.11.2 REVENUE ANALYSIS
25.1.11.3 GEOGRAPHIC PRESENCE
25.1.11.4 MAJOR DEALS
25.1.11.5 M&A
25.1.11.6 INNOVATIONS
25.1.11.7 EVENTS
25.1.11.8 OTHERS
25.1.11.9 PRODUCT PORTFOLIO
25.1.11.10 RECENT DEVELOPMENTS
25.1.11.11 RECENT NEWS
25.1.12 INSUD PHARMA, S.L.
25.1.12.1 COMPANY OVERVIEW
25.1.12.2 REVENUE ANALYSIS
25.1.12.3 GEOGRAPHIC PRESENCE
25.1.12.4 MAJOR DEALS
25.1.12.5 M&A
25.1.12.6 COLLABORATION
25.1.12.7 PRODUCT ACQUISITION
25.1.12.8 PRODUCTION CAPACITY EXPANSION
25.1.12.9 INNOVATIONS
25.1.12.10 PRODUCT LAUNCHES
25.1.12.11 OTHERS
25.1.12.12 PRODUCT PORTFOLIO
25.1.12.13 RECENT DEVELOPMENTS
25.1.12.14 RECENT NEWS
25.1.13 COOPERSURGICAL, INC.
25.1.13.1 COMPANY OVERVIEW
25.1.13.2 REVENUE ANALYSIS
25.1.13.3 GEOGRAPHIC PRESENCE
25.1.13.4 MAJOR DEALS
25.1.13.5 M&A
25.1.13.6 PRODUCT ACQUISITION
25.1.13.7 PRODUCTION CAPACITY EXPANSION
25.1.13.8 INNOVATIONS
25.1.13.9 PRODUCT LAUNCHES
25.1.13.10 EVENTS
25.1.13.11 CONFERENCES
25.1.13.12 WEBINARS
25.1.13.13 OTHERS
25.1.13.14 PRODUCT PORTFOLIO
25.1.13.15 RECENT DEVELOPMENTS
25.1.13.16 RECENT NEWS
25.1.14 MANKIND
25.1.14.1 COMPANY OVERVIEW
25.1.14.2 REVENUE ANALYSIS
25.1.14.3 GEOGRAPHIC PRESENCE
25.1.14.4 MAJOR DEALS
25.1.14.5 M&A
25.1.14.6 COLLABORATION
25.1.14.7 PRODUCTION CAPACITY EXPANSION
25.1.14.8 INNOVATIONS
25.1.14.9 PRODUCT LAUNCHES
25.1.14.10 EVENTS
25.1.14.11 OTHERS
25.1.14.12 PRODUCT PORTFOLIO
25.1.14.13 RECENT DEVELOPMENTS
25.1.14.14 RECENT NEWS
25.2 CONDOM AND BARRIER-METHOD MANUFACTURERS
25.2.1 CHURCH & DWIGHT CO., INC.
25.2.1.1 COMPANY OVERVIEW
25.2.1.2 REVENUE ANALYSIS
25.2.1.3 GEOGRAPHIC PRESENCE
25.2.1.4 M&A
25.2.1.5 INNOVATIONS
25.2.1.6 PRODUCT LAUNCHES
25.2.1.7 OTHERS
25.2.1.8 PRODUCT PORTFOLIO
25.2.1.9 RECENT DEVELOPMENTS
25.2.1.10 RECENT NEWS
25.2.2 RECKITT
25.2.2.1 COMPANY OVERVIEW
25.2.2.2 REVENUE ANALYSIS
25.2.2.3 GEOGRAPHIC PRESENCE
25.2.2.4 MAJOR DEALS
25.2.2.5 M&A
25.2.2.6 INNOVATIONS
25.2.2.7 PRODUCT LAUNCHES
25.2.2.8 EVENTS
25.2.2.9 OTHERS
25.2.2.10 PRODUCT PORTFOLIO
25.2.2.11 RECENT DEVELOPMENTS
25.2.2.12 RECENT NEWS
25.2.3 OKAMOTO INDUSTRIES, INC.
25.2.3.1 COMPANY OVERVIEW
25.2.3.2 REVENUE ANALYSIS
25.2.3.3 GEOGRAPHIC PRESENCE
25.2.3.4 PRODUCTION CAPACITY EXPANSION
25.2.3.5 INNOVATIONS
25.2.3.6 PRODUCT LAUNCHES
25.2.3.7 OTHERS
25.2.3.8 PRODUCT PORTFOLIO
25.2.3.9 RECENT DEVELOPMENTS
25.2.3.10 RECENT NEWS
25.2.4 SAGAMI RUBBER INDUSTRIES CO., LTD.
25.2.4.1 COMPANY OVERVIEW
25.2.4.2 REVENUE ANALYSIS
25.2.4.3 GEOGRAPHIC PRESENCE
25.2.4.4 COLLABORATION
25.2.4.5 PRODUCTION CAPACITY EXPANSION
25.2.4.6 INNOVATIONS
25.2.4.7 PRODUCT LAUNCHES
25.2.4.8 EVENTS
25.2.4.9 OTHERS
25.2.4.10 PRODUCT PORTFOLIO
25.2.4.11 RECENT DEVELOPMENTS
25.2.4.12 RECENT NEWS
25.2.5 FUJI LATEX CO., LTD.
25.2.5.1 COMPANY OVERVIEW
25.2.5.2 REVENUE ANALYSIS
25.2.5.3 GEOGRAPHIC PRESENCE
25.2.5.4 COLLABORATION
25.2.5.5 PRODUCTION CAPACITY EXPANSION
25.2.5.6 INNOVATIONS
25.2.5.7 PRODUCT LAUNCHES
25.2.5.8 EVENTS
25.2.5.9 OTHERS
25.2.5.10 PRODUCT PORTFOLIO
25.2.5.11 RECENT DEVELOPMENTS
25.2.5.12 RECENT NEWS
25.2.6 KAREX BERHAD
25.2.6.1 COMPANY OVERVIEW
25.2.6.2 REVENUE ANALYSIS
25.2.6.3 GEOGRAPHIC PRESENCE
25.2.6.4 COLLABORATION
25.2.6.5 PRODUCTION CAPACITY EXPANSION
25.2.6.6 INNOVATIONS
25.2.6.7 PRODUCT LAUNCHES
25.2.6.8 EVENTS
25.2.6.9 OTHERS
25.2.6.10 PRODUCT PORTFOLIO
25.2.6.11 RECENT DEVELOPMENTS
25.2.6.12 RECENT NEWS
25.2.7 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED
25.2.7.1 COMPANY OVERVIEW
25.2.7.2 REVENUE ANALYSIS
25.2.7.3 GEOGRAPHIC PRESENCE
25.2.7.4 MAJOR DEALS
25.2.7.5 COLLABORATION
25.2.7.6 PRODUCT ACQUISITION
25.2.7.7 PRODUCTION CAPACITY EXPANSION
25.2.7.8 INNOVATIONS
25.2.7.9 PRODUCT LAUNCHES
25.2.7.10 EVENTS
25.2.7.11 OTHERS
25.2.7.12 PRODUCT PORTFOLIO
25.2.7.13 RECENT DEVELOPMENTS
25.2.7.14 RECENT NEWS
25.2.8 MAYER LABORATORIES, INC.
25.2.8.1 COMPANY OVERVIEW
25.2.8.2 GEOGRAPHIC PRESENCE
25.2.8.3 COLLABORATION
25.2.8.4 INNOVATIONS
25.2.8.5 OTHERS
25.2.8.6 PRODUCT PORTFOLIO
25.2.8.7 RECENT DEVELOPMENTS
25.2.8.8 RECENT NEWS
25.2.9 CUPID
25.2.9.1 COMPANY OVERVIEW
25.2.9.2 REVENUE ANALYSIS
25.2.9.3 GEOGRAPHIC PRESENCE
25.2.9.4 MAJOR DEALS
25.2.9.5 M&A
25.2.9.6 COLLABORATION
25.2.9.7 PRODUCTION CAPACITY EXPANSION
25.2.9.8 INNOVATIONS
25.2.9.9 PRODUCT LAUNCHES
25.2.9.10 OTHERS
25.2.9.11 PRODUCT PORTFOLIO
25.2.9.12 RECENT DEVELOPMENTS
25.2.9.13 RECENT NEWS
25.2.10 TTK
25.2.10.1 COMPANY OVERVIEW
25.2.10.2 REVENUE ANALYSIS
25.2.10.3 GEOGRAPHIC PRESENCE
25.2.10.4 MAJOR DEALS
25.2.10.5 COLLABORATION
25.2.10.6 PRODUCTION CAPACITY EXPANSION
25.2.10.7 JOINT VENTURES
25.2.10.8 INNOVATIONS
25.2.10.9 PRODUCT LAUNCHES
25.2.10.10 OTHERS
25.2.10.11 PRODUCT PORTFOLIO
25.2.10.12 RECENT DEVELOPMENTS
25.2.10.13 RECENT NEWS
25.3 DEVICE AND GENERIC MAKERS SERVING PUBLIC-SECTOR PROGRAMMES
25.3.1 PREGNA INTERNATIONAL LIMITED
25.3.1.1 COMPANY OVERVIEW
25.3.1.2 GEOGRAPHIC PRESENCE
25.3.1.3 MAJOR DEALS
25.3.1.4 INNOVATIONS
25.3.1.5 PRODUCT LAUNCHES
25.3.1.6 OTHERS
25.3.1.7 PRODUCT PORTFOLIO
25.3.1.8 RECENT DEVELOPMENTS
25.3.1.9 RECENT NEWS
25.3.2 SMB CORPORATION OF INDIA
25.3.2.1 COMPANY OVERVIEW
25.3.2.2 GEOGRAPHIC PRESENCE
25.3.2.3 PRODUCTION CAPACITY EXPANSION
25.3.2.4 INNOVATIONS
25.3.2.5 PRODUCT LAUNCHES
25.3.2.6 EVENTS
25.3.2.7 CONFERENCES
25.3.2.8 OTHERS
25.3.2.9 PRODUCT PORTFOLIO
25.3.2.10 RECENT DEVELOPMENTS
25.3.2.11 RECENT NEWS
25.3.3 EUROGINE
25.3.3.1 COMPANY OVERVIEW
25.3.3.2 REVENUE ANALYSIS
25.3.3.3 GEOGRAPHIC PRESENCE
25.3.3.4 COLLABORATION
25.3.3.5 PRODUCTION CAPACITY EXPANSION
25.3.3.6 INNOVATIONS
25.3.3.7 EVENTS
25.3.3.8 SYMPOSIUMS
25.3.3.9 OTHERS
25.3.3.10 PRODUCT PORTFOLIO
25.3.3.11 RECENT DEVELOPMENTS
25.3.3.12 RECENT NEWS
25.3.4 OCON MEDICAL LTD.
25.3.4.1 COMPANY OVERVIEW
25.3.4.2 REVENUE ANALYSIS
25.3.4.3 GEOGRAPHIC PRESENCE
25.3.4.4 MAJOR DEALS
25.3.4.5 COLLABORATION
25.3.4.6 PRODUCTION CAPACITY EXPANSION
25.3.4.7 INNOVATIONS
25.3.4.8 EVENTS
25.3.4.9 OTHERS
25.3.4.10 PRODUCT PORTFOLIO
25.3.4.11 RECENT DEVELOPMENTS
25.3.4.12 RECENT NEWS
25.3.5 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD.
25.3.5.1 COMPANY OVERVIEW
25.3.5.2 REVENUE ANALYSIS
25.3.5.3 GEOGRAPHIC PRESENCE
25.3.5.4 COLLABORATION
25.3.5.5 PRODUCTION CAPACITY EXPANSION
25.3.5.6 INNOVATIONS
25.3.5.7 EVENTS
25.3.5.8 CONFERENCES
25.3.5.9 OTHERS
25.3.5.10 PRODUCT PORTFOLIO
25.3.5.11 RECENT DEVELOPMENTS
25.3.5.12 RECENT NEWS
25.3.6 HLL LIFECARE LIMITED
25.3.6.1 COMPANY OVERVIEW
25.3.6.2 REVENUE ANALYSIS
25.3.6.3 GEOGRAPHIC PRESENCE
25.3.6.4 MAJOR DEALS
25.3.6.5 COLLABORATION
25.3.6.6 PRODUCTION CAPACITY EXPANSION
25.3.6.7 JOINT VENTURES
25.3.6.8 INNOVATIONS
25.3.6.9 PRODUCT LAUNCHES
25.3.6.10 EVENTS
25.3.6.11 OTHERS
25.3.6.12 PRODUCT PORTFOLIO
25.3.6.13 RECENT DEVELOPMENTS
25.3.6.14 RECENT NEWS
26 RELATED REPORTS
27 CONCLUSION
28 QUESTIONNAIRE
List of Table
TABLE 1 GLOBAL CONTRACEPTIVE MARKET: CHALLENGE MATRIX
TABLE 2 GLOBAL CONTRACEPTIVE MARKET: RESEARCH SNAPSHOT
TABLE 3 WOMEN USING CONTRACEPTION BY REGION, 2015, 2025 AND 2030 (MILLION)
TABLE 4 CURRENT CONTRACEPTIVE USE AMONG WOMEN AGED 15-49 IN THE UNITED STATES, BY METHOD, FROM THE LATEST NSFG SURVEY
TABLE 5 NEED FOR AND USE OF FAMILY PLANNING, WORLD AND INDIA
TABLE 6 DISCONTINUATION, SWITCHING AND ABANDONMENT OF REVERSIBLE METHODS IN 61 DHS COUNTRIES
TABLE 7 PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY IN THE FIRST YEAR OF USE, BY METHOD
TABLE 8 EASE OF REGULATORY APPROVAL FOR CONTRACEPTIVES, BY GEOGRAPHY
TABLE 9 APPROVAL ROUTES BY CONTRACEPTIVE TYPE
TABLE 10 CONTRACEPTIVE PIPELINE, 22 CANDIDATES LISTED, BY PHASE AND TYPE
TABLE 11 GLOBAL CONTRACEPTIVE PIPELINE, CANDIDATES BY HIGHEST PHASE REACHED
TABLE 12 PHASE III CONTRACEPTIVE CANDIDATES
TABLE 13 PHASE II CONTRACEPTIVE CANDIDATES
TABLE 14 PHASE I CONTRACEPTIVE CANDIDATES
TABLE 15 PRE-CLINICAL AND RESEARCH-STAGE CONTRACEPTIVE CANDIDATES
TABLE 16 LEADING MARKETED CONTRACEPTIVE DRUGS AND DEVICES
TABLE 17 DOSING INTERVAL BY METHOD
TABLE 18 REGULATORY MILESTONES FOR LEADING CONTRACEPTIVES
TABLE 19 GLOBAL CONTRACEPTIVE MARKET BY SEGMENT, USD MILLION, 2025 AND 2033
TABLE 20 SELECTED CONTRACEPTIVE CLINICAL PROGRAMMES AND THEIR LATEST STATUS
TABLE 21 RECENT CONTRACEPTIVE APPROVALS AND LABEL CHANGES
TABLE 22 MAJOR CONTRACEPTIVE ACQUISITIONS AND LICENCES SINCE 2024
TABLE 23 NUMBER OF WOMEN USING EACH CONTRACEPTIVE METHOD WORLDWIDE, 2020
TABLE 24 COMPARATIVE ANALYSIS OF CONTRACEPTIVE DEVELOPMENT APPROACHES
TABLE 25 CONTRACEPTIVE REGULATORY MILESTONES SINCE 2018
TABLE 26 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS IN CONTRACEPTION
TABLE 27 GLOBAL CONTRACEPTIVE MARKET: DRIVERS IMPACT ANALYSIS
TABLE 28 GLOBAL CONTRACEPTIVE MARKET: RESTRAINTS IMPACT ANALYSIS
TABLE 29 GLOBAL CONTRACEPTIVE MARKET: OPPORTUNITIES IMPACT ANALYSIS
TABLE 30 GLOBAL CONTRACEPTIVE MARKET: CHALLENGES IMPACT ANALYSIS
TABLE 31 GLOBAL CONTRACEPTIVE MARKET: TRENDS IMPACT ANALYSIS
TABLE 32 GLOBAL CONTRACEPTIVE MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
TABLE 33 GLOBAL CONTRACEPTIVE MARKET: PESTEL ANALYSIS
TABLE 34 FDA ORANGE BOOK PATENTS LISTED FOR BRANDED CONTRACEPTIVES
TABLE 35 ORANGE BOOK PATENTS AND EXCLUSIVITIES EXPIRING 2026 TO 2029
TABLE 36 COMPANY EVALUATION QUADRANT, GLOBAL CONTRACEPTIVE MARKET
TABLE 37 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 38 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 39 CONTRACEPTIVE DRUGS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 40 CONTRACEPTIVE DRUGS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 41 ORAL CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 42 ORAL CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 43 COMBINED ORAL CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 44 COMBINED ORAL CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 45 MONOPHASIC PILLS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 46 MONOPHASIC PILLS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 47 PROGESTIN-ONLY PILLS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 48 PROGESTIN-ONLY PILLS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 49 EMERGENCY CONTRACEPTIVE PILLS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 50 EMERGENCY CONTRACEPTIVE PILLS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 51 LEVONORGESTREL-BASED, BY TYPE, 2018-2025 (USD MILLION)
TABLE 52 LEVONORGESTREL-BASED, BY TYPE, 2026-2033 (USD MILLION)
TABLE 53 INJECTABLE CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 54 INJECTABLE CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 55 PROGESTIN-ONLY INJECTABLES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 56 PROGESTIN-ONLY INJECTABLES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 57 DEPOT MEDROXYPROGESTERONE ACETATE (DMPA), BY TYPE, 2018-2025 (USD MILLION)
TABLE 58 DEPOT MEDROXYPROGESTERONE ACETATE (DMPA), BY TYPE, 2026-2033 (USD MILLION)
TABLE 59 COMBINED INJECTABLE CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 60 COMBINED INJECTABLE CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 61 TRANSDERMAL CONTRACEPTIVE PATCHES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 62 TRANSDERMAL CONTRACEPTIVE PATCHES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 63 COMBINED HORMONAL PATCHES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 64 COMBINED HORMONAL PATCHES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 65 VAGINAL HORMONAL CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 66 VAGINAL HORMONAL CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 67 MONTHLY VAGINAL RINGS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 68 MONTHLY VAGINAL RINGS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 69 EXTENDED-USE VAGINAL RINGS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 70 EXTENDED-USE VAGINAL RINGS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 71 CONTRACEPTIVE DEVICES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 72 CONTRACEPTIVE DEVICES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 73 CONDOMS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 74 CONDOMS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 75 MALE CONDOMS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 76 MALE CONDOMS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 77 LATEX CONDOMS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 78 LATEX CONDOMS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 79 NON-LATEX CONDOMS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 80 NON-LATEX CONDOMS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 81 FEMALE / INTERNAL CONDOMS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 82 FEMALE / INTERNAL CONDOMS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 83 INTRAUTERINE DEVICES (IUDS), BY TYPE, 2018-2025 (USD MILLION)
TABLE 84 INTRAUTERINE DEVICES (IUDS), BY TYPE, 2026-2033 (USD MILLION)
TABLE 85 COPPER IUDS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 86 COPPER IUDS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 87 COPPER T-SHAPED IUDS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 88 COPPER T-SHAPED IUDS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 89 HORMONAL IUDS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 90 HORMONAL IUDS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 91 LEVONORGESTREL-RELEASING IUDS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 92 LEVONORGESTREL-RELEASING IUDS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 93 SUBDERMAL CONTRACEPTIVE IMPLANTS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 94 SUBDERMAL CONTRACEPTIVE IMPLANTS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 95 SINGLE-ROD IMPLANTS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 96 SINGLE-ROD IMPLANTS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 97 DOUBLE-ROD IMPLANTS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 98 DOUBLE-ROD IMPLANTS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 99 OTHER BARRIER CONTRACEPTIVE DEVICES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 100 OTHER BARRIER CONTRACEPTIVE DEVICES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 101 DIAPHRAGMS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 102 DIAPHRAGMS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 103 FEMALE STERILIZATION DEVICES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 104 FEMALE STERILIZATION DEVICES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 105 CONTRACEPTIVE SPERMICIDES & ADJUNCT PRODUCTS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 106 CONTRACEPTIVE SPERMICIDES & ADJUNCT PRODUCTS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 107 SPERMICIDAL GELS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 108 SPERMICIDAL GELS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 109 SPERMICIDAL FOAMS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 110 SPERMICIDAL FOAMS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 111 SPERMICIDAL FILMS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 112 SPERMICIDAL FILMS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 113 SPERMICIDAL SUPPOSITORIES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 114 SPERMICIDAL SUPPOSITORIES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 115 VAGINAL PH MODULATORS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 116 VAGINAL PH MODULATORS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 117 GLOBAL CONTRACEPTIVE MARKET, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 118 GLOBAL CONTRACEPTIVE MARKET, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 119 ESTROGEN + PROGESTIN COMBINATION CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 120 ESTROGEN + PROGESTIN COMBINATION CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 121 PROGESTIN-ONLY CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 122 PROGESTIN-ONLY CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 123 NON-HORMONAL CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 124 NON-HORMONAL CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 125 GLOBAL CONTRACEPTIVE MARKET, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 126 GLOBAL CONTRACEPTIVE MARKET, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 127 SHORT-ACTING REVERSIBLE CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 128 SHORT-ACTING REVERSIBLE CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 129 INTERMEDIATE-ACTING CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 130 INTERMEDIATE-ACTING CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 131 LONG-ACTING REVERSIBLE CONTRACEPTIVES (LARC), BY TYPE, 2018-2025 (USD MILLION)
TABLE 132 LONG-ACTING REVERSIBLE CONTRACEPTIVES (LARC), BY TYPE, 2026-2033 (USD MILLION)
TABLE 133 LARC INTRAUTERINE DEVICES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 134 LARC INTRAUTERINE DEVICES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 135 PERMANENT CONTRACEPTION, BY TYPE, 2018-2025 (USD MILLION)
TABLE 136 PERMANENT CONTRACEPTION, BY TYPE, 2026-2033 (USD MILLION)
TABLE 137 GLOBAL CONTRACEPTIVE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 138 GLOBAL CONTRACEPTIVE MARKET, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 139 ORAL, BY TYPE, 2018-2025 (USD MILLION)
TABLE 140 ORAL, BY TYPE, 2026-2033 (USD MILLION)
TABLE 141 INJECTABLE, BY TYPE, 2018-2025 (USD MILLION)
TABLE 142 INJECTABLE, BY TYPE, 2026-2033 (USD MILLION)
TABLE 143 TRANSDERMAL, BY TYPE, 2018-2025 (USD MILLION)
TABLE 144 TRANSDERMAL, BY TYPE, 2026-2033 (USD MILLION)
TABLE 145 VAGINAL, BY TYPE, 2018-2025 (USD MILLION)
TABLE 146 VAGINAL, BY TYPE, 2026-2033 (USD MILLION)
TABLE 147 INTRAUTERINE, BY TYPE, 2018-2025 (USD MILLION)
TABLE 148 INTRAUTERINE, BY TYPE, 2026-2033 (USD MILLION)
TABLE 149 SUBDERMAL, BY TYPE, 2018-2025 (USD MILLION)
TABLE 150 SUBDERMAL, BY TYPE, 2026-2033 (USD MILLION)
TABLE 151 EXTERNAL APPLICATION, BY TYPE, 2018-2025 (USD MILLION)
TABLE 152 EXTERNAL APPLICATION, BY TYPE, 2026-2033 (USD MILLION)
TABLE 153 GLOBAL CONTRACEPTIVE MARKET, BY GENDER, 2018-2025 (USD MILLION)
TABLE 154 GLOBAL CONTRACEPTIVE MARKET, BY GENDER, 2026-2033 (USD MILLION)
TABLE 155 FEMALE CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 156 FEMALE CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 157 MALE CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 158 MALE CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 159 GLOBAL CONTRACEPTIVE MARKET, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 160 GLOBAL CONTRACEPTIVE MARKET, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 161 PRESCRIPTION CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 162 PRESCRIPTION CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 163 OVER-THE-COUNTER (OTC) CONTRACEPTIVES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 164 OVER-THE-COUNTER (OTC) CONTRACEPTIVES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 165 GLOBAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 166 GLOBAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 167 GLOBAL CONTRACEPTIVE MARKET, BY END USER, 2018-2025 (USD MILLION)
TABLE 168 GLOBAL CONTRACEPTIVE MARKET, BY END USER, 2026-2033 (USD MILLION)
TABLE 169 HOSPITALS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 170 HOSPITALS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 171 GYNECOLOGY & OBSTETRIC CLINICS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 172 GYNECOLOGY & OBSTETRIC CLINICS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 173 FAMILY PLANNING CENTERS, BY TYPE, 2018-2025 (USD MILLION)
TABLE 174 FAMILY PLANNING CENTERS, BY TYPE, 2026-2033 (USD MILLION)
TABLE 175 GLOBAL CONTRACEPTIVE MARKET, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 176 GLOBAL CONTRACEPTIVE MARKET, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 177 ONLINE PHARMACIES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 178 ONLINE PHARMACIES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 179 DIRECT / INSTITUTIONAL SALES, BY TYPE, 2018-2025 (USD MILLION)
TABLE 180 DIRECT / INSTITUTIONAL SALES, BY TYPE, 2026-2033 (USD MILLION)
TABLE 181 GLOBAL CONTRACEPTIVE MARKET, BY REGION, 2018-2025 (USD MILLION)
TABLE 182 GLOBAL CONTRACEPTIVE MARKET, BY REGION, 2026-2033 (USD MILLION)
TABLE 183 NORTH AMERICA, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 184 NORTH AMERICA, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 185 NORTH AMERICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 186 NORTH AMERICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 187 NORTH AMERICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 188 NORTH AMERICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 189 NORTH AMERICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 190 NORTH AMERICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 191 NORTH AMERICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 192 NORTH AMERICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 193 NORTH AMERICA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 194 NORTH AMERICA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 195 NORTH AMERICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 196 NORTH AMERICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 197 NORTH AMERICA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 198 NORTH AMERICA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 199 NORTH AMERICA, BY END USER, 2018-2025 (USD MILLION)
TABLE 200 NORTH AMERICA, BY END USER, 2026-2033 (USD MILLION)
TABLE 201 NORTH AMERICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 202 NORTH AMERICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 203 U.S., BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 204 U.S., BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 205 U.S., BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 206 U.S., BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 207 U.S., BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 208 U.S., BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 209 U.S., BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 210 U.S., BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 211 U.S., BY GENDER, 2018-2025 (USD MILLION)
TABLE 212 U.S., BY GENDER, 2026-2033 (USD MILLION)
TABLE 213 U.S., BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 214 U.S., BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 215 U.S., BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 216 U.S., BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 217 U.S., BY END USER, 2018-2025 (USD MILLION)
TABLE 218 U.S., BY END USER, 2026-2033 (USD MILLION)
TABLE 219 U.S., BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 220 U.S., BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 221 CANADA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 222 CANADA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 223 CANADA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 224 CANADA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 225 CANADA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 226 CANADA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 227 CANADA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 228 CANADA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 229 CANADA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 230 CANADA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 231 CANADA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 232 CANADA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 233 CANADA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 234 CANADA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 235 CANADA, BY END USER, 2018-2025 (USD MILLION)
TABLE 236 CANADA, BY END USER, 2026-2033 (USD MILLION)
TABLE 237 CANADA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 238 CANADA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 239 MEXICO, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 240 MEXICO, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 241 MEXICO, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 242 MEXICO, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 243 MEXICO, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 244 MEXICO, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 245 MEXICO, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 246 MEXICO, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 247 MEXICO, BY GENDER, 2018-2025 (USD MILLION)
TABLE 248 MEXICO, BY GENDER, 2026-2033 (USD MILLION)
TABLE 249 MEXICO, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 250 MEXICO, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 251 MEXICO, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 252 MEXICO, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 253 MEXICO, BY END USER, 2018-2025 (USD MILLION)
TABLE 254 MEXICO, BY END USER, 2026-2033 (USD MILLION)
TABLE 255 MEXICO, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 256 MEXICO, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 257 EUROPE, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 258 EUROPE, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 259 EUROPE, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 260 EUROPE, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 261 EUROPE, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 262 EUROPE, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 263 EUROPE, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 264 EUROPE, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 265 EUROPE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 266 EUROPE, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 267 EUROPE, BY GENDER, 2018-2025 (USD MILLION)
TABLE 268 EUROPE, BY GENDER, 2026-2033 (USD MILLION)
TABLE 269 EUROPE, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 270 EUROPE, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 271 EUROPE, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 272 EUROPE, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 273 EUROPE, BY END USER, 2018-2025 (USD MILLION)
TABLE 274 EUROPE, BY END USER, 2026-2033 (USD MILLION)
TABLE 275 EUROPE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 276 EUROPE, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 277 GERMANY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 278 GERMANY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 279 GERMANY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 280 GERMANY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 281 GERMANY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 282 GERMANY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 283 GERMANY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 284 GERMANY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 285 GERMANY, BY GENDER, 2018-2025 (USD MILLION)
TABLE 286 GERMANY, BY GENDER, 2026-2033 (USD MILLION)
TABLE 287 GERMANY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 288 GERMANY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 289 GERMANY, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 290 GERMANY, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 291 GERMANY, BY END USER, 2018-2025 (USD MILLION)
TABLE 292 GERMANY, BY END USER, 2026-2033 (USD MILLION)
TABLE 293 GERMANY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 294 GERMANY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 295 U.K., BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 296 U.K., BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 297 U.K., BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 298 U.K., BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 299 U.K., BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 300 U.K., BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 301 U.K., BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 302 U.K., BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 303 U.K., BY GENDER, 2018-2025 (USD MILLION)
TABLE 304 U.K., BY GENDER, 2026-2033 (USD MILLION)
TABLE 305 U.K., BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 306 U.K., BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 307 U.K., BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 308 U.K., BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 309 U.K., BY END USER, 2018-2025 (USD MILLION)
TABLE 310 U.K., BY END USER, 2026-2033 (USD MILLION)
TABLE 311 U.K., BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 312 U.K., BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 313 ITALY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 314 ITALY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 315 ITALY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 316 ITALY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 317 ITALY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 318 ITALY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 319 ITALY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 320 ITALY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 321 ITALY, BY GENDER, 2018-2025 (USD MILLION)
TABLE 322 ITALY, BY GENDER, 2026-2033 (USD MILLION)
TABLE 323 ITALY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 324 ITALY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 325 ITALY, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 326 ITALY, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 327 ITALY, BY END USER, 2018-2025 (USD MILLION)
TABLE 328 ITALY, BY END USER, 2026-2033 (USD MILLION)
TABLE 329 ITALY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 330 ITALY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 331 FRANCE, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 332 FRANCE, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 333 FRANCE, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 334 FRANCE, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 335 FRANCE, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 336 FRANCE, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 337 FRANCE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 338 FRANCE, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 339 FRANCE, BY GENDER, 2018-2025 (USD MILLION)
TABLE 340 FRANCE, BY GENDER, 2026-2033 (USD MILLION)
TABLE 341 FRANCE, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 342 FRANCE, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 343 FRANCE, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 344 FRANCE, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 345 FRANCE, BY END USER, 2018-2025 (USD MILLION)
TABLE 346 FRANCE, BY END USER, 2026-2033 (USD MILLION)
TABLE 347 FRANCE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 348 FRANCE, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 349 SPAIN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 350 SPAIN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 351 SPAIN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 352 SPAIN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 353 SPAIN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 354 SPAIN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 355 SPAIN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 356 SPAIN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 357 SPAIN, BY GENDER, 2018-2025 (USD MILLION)
TABLE 358 SPAIN, BY GENDER, 2026-2033 (USD MILLION)
TABLE 359 SPAIN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 360 SPAIN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 361 SPAIN, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 362 SPAIN, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 363 SPAIN, BY END USER, 2018-2025 (USD MILLION)
TABLE 364 SPAIN, BY END USER, 2026-2033 (USD MILLION)
TABLE 365 SPAIN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 366 SPAIN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 367 SWITZERLAND, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 368 SWITZERLAND, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 369 SWITZERLAND, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 370 SWITZERLAND, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 371 SWITZERLAND, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 372 SWITZERLAND, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 373 SWITZERLAND, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 374 SWITZERLAND, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 375 SWITZERLAND, BY GENDER, 2018-2025 (USD MILLION)
TABLE 376 SWITZERLAND, BY GENDER, 2026-2033 (USD MILLION)
TABLE 377 SWITZERLAND, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 378 SWITZERLAND, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 379 SWITZERLAND, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 380 SWITZERLAND, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 381 SWITZERLAND, BY END USER, 2018-2025 (USD MILLION)
TABLE 382 SWITZERLAND, BY END USER, 2026-2033 (USD MILLION)
TABLE 383 SWITZERLAND, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 384 SWITZERLAND, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 385 RUSSIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 386 RUSSIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 387 RUSSIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 388 RUSSIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 389 RUSSIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 390 RUSSIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 391 RUSSIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 392 RUSSIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 393 RUSSIA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 394 RUSSIA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 395 RUSSIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 396 RUSSIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 397 RUSSIA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 398 RUSSIA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 399 RUSSIA, BY END USER, 2018-2025 (USD MILLION)
TABLE 400 RUSSIA, BY END USER, 2026-2033 (USD MILLION)
TABLE 401 RUSSIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 402 RUSSIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 403 TURKEY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 404 TURKEY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 405 TURKEY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 406 TURKEY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 407 TURKEY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 408 TURKEY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 409 TURKEY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 410 TURKEY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 411 TURKEY, BY GENDER, 2018-2025 (USD MILLION)
TABLE 412 TURKEY, BY GENDER, 2026-2033 (USD MILLION)
TABLE 413 TURKEY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 414 TURKEY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 415 TURKEY, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 416 TURKEY, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 417 TURKEY, BY END USER, 2018-2025 (USD MILLION)
TABLE 418 TURKEY, BY END USER, 2026-2033 (USD MILLION)
TABLE 419 TURKEY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 420 TURKEY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 421 BELGIUM, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 422 BELGIUM, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 423 BELGIUM, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 424 BELGIUM, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 425 BELGIUM, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 426 BELGIUM, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 427 BELGIUM, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 428 BELGIUM, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 429 BELGIUM, BY GENDER, 2018-2025 (USD MILLION)
TABLE 430 BELGIUM, BY GENDER, 2026-2033 (USD MILLION)
TABLE 431 BELGIUM, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 432 BELGIUM, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 433 BELGIUM, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 434 BELGIUM, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 435 BELGIUM, BY END USER, 2018-2025 (USD MILLION)
TABLE 436 BELGIUM, BY END USER, 2026-2033 (USD MILLION)
TABLE 437 BELGIUM, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 438 BELGIUM, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 439 NETHERLANDS, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 440 NETHERLANDS, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 441 NETHERLANDS, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 442 NETHERLANDS, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 443 NETHERLANDS, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 444 NETHERLANDS, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 445 NETHERLANDS, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 446 NETHERLANDS, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 447 NETHERLANDS, BY GENDER, 2018-2025 (USD MILLION)
TABLE 448 NETHERLANDS, BY GENDER, 2026-2033 (USD MILLION)
TABLE 449 NETHERLANDS, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 450 NETHERLANDS, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 451 NETHERLANDS, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 452 NETHERLANDS, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 453 NETHERLANDS, BY END USER, 2018-2025 (USD MILLION)
TABLE 454 NETHERLANDS, BY END USER, 2026-2033 (USD MILLION)
TABLE 455 NETHERLANDS, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 456 NETHERLANDS, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 457 DENMARK, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 458 DENMARK, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 459 DENMARK, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 460 DENMARK, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 461 DENMARK, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 462 DENMARK, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 463 DENMARK, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 464 DENMARK, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 465 DENMARK, BY GENDER, 2018-2025 (USD MILLION)
TABLE 466 DENMARK, BY GENDER, 2026-2033 (USD MILLION)
TABLE 467 DENMARK, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 468 DENMARK, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 469 DENMARK, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 470 DENMARK, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 471 DENMARK, BY END USER, 2018-2025 (USD MILLION)
TABLE 472 DENMARK, BY END USER, 2026-2033 (USD MILLION)
TABLE 473 DENMARK, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 474 DENMARK, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 475 NORWAY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 476 NORWAY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 477 NORWAY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 478 NORWAY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 479 NORWAY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 480 NORWAY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 481 NORWAY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 482 NORWAY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 483 NORWAY, BY GENDER, 2018-2025 (USD MILLION)
TABLE 484 NORWAY, BY GENDER, 2026-2033 (USD MILLION)
TABLE 485 NORWAY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 486 NORWAY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 487 NORWAY, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 488 NORWAY, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 489 NORWAY, BY END USER, 2018-2025 (USD MILLION)
TABLE 490 NORWAY, BY END USER, 2026-2033 (USD MILLION)
TABLE 491 NORWAY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 492 NORWAY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 493 FINLAND, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 494 FINLAND, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 495 FINLAND, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 496 FINLAND, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 497 FINLAND, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 498 FINLAND, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 499 FINLAND, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 500 FINLAND, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 501 FINLAND, BY GENDER, 2018-2025 (USD MILLION)
TABLE 502 FINLAND, BY GENDER, 2026-2033 (USD MILLION)
TABLE 503 FINLAND, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 504 FINLAND, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 505 FINLAND, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 506 FINLAND, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 507 FINLAND, BY END USER, 2018-2025 (USD MILLION)
TABLE 508 FINLAND, BY END USER, 2026-2033 (USD MILLION)
TABLE 509 FINLAND, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 510 FINLAND, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 511 SWEDEN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 512 SWEDEN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 513 SWEDEN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 514 SWEDEN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 515 SWEDEN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 516 SWEDEN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 517 SWEDEN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 518 SWEDEN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 519 SWEDEN, BY GENDER, 2018-2025 (USD MILLION)
TABLE 520 SWEDEN, BY GENDER, 2026-2033 (USD MILLION)
TABLE 521 SWEDEN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 522 SWEDEN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 523 SWEDEN, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 524 SWEDEN, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 525 SWEDEN, BY END USER, 2018-2025 (USD MILLION)
TABLE 526 SWEDEN, BY END USER, 2026-2033 (USD MILLION)
TABLE 527 SWEDEN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 528 SWEDEN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 529 REST OF EUROPE, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 530 REST OF EUROPE, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 531 REST OF EUROPE, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 532 REST OF EUROPE, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 533 REST OF EUROPE, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 534 REST OF EUROPE, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 535 REST OF EUROPE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 536 REST OF EUROPE, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 537 REST OF EUROPE, BY GENDER, 2018-2025 (USD MILLION)
TABLE 538 REST OF EUROPE, BY GENDER, 2026-2033 (USD MILLION)
TABLE 539 REST OF EUROPE, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 540 REST OF EUROPE, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 541 REST OF EUROPE, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 542 REST OF EUROPE, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 543 REST OF EUROPE, BY END USER, 2018-2025 (USD MILLION)
TABLE 544 REST OF EUROPE, BY END USER, 2026-2033 (USD MILLION)
TABLE 545 REST OF EUROPE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 546 REST OF EUROPE, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 547 ASIA PACIFIC, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 548 ASIA PACIFIC, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 549 ASIA PACIFIC, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 550 ASIA PACIFIC, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 551 ASIA PACIFIC, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 552 ASIA PACIFIC, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 553 ASIA PACIFIC, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 554 ASIA PACIFIC, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 555 ASIA PACIFIC, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 556 ASIA PACIFIC, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 557 ASIA PACIFIC, BY GENDER, 2018-2025 (USD MILLION)
TABLE 558 ASIA PACIFIC, BY GENDER, 2026-2033 (USD MILLION)
TABLE 559 ASIA PACIFIC, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 560 ASIA PACIFIC, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 561 ASIA PACIFIC, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 562 ASIA PACIFIC, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 563 ASIA PACIFIC, BY END USER, 2018-2025 (USD MILLION)
TABLE 564 ASIA PACIFIC, BY END USER, 2026-2033 (USD MILLION)
TABLE 565 ASIA PACIFIC, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 566 ASIA PACIFIC, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 567 JAPAN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 568 JAPAN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 569 JAPAN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 570 JAPAN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 571 JAPAN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 572 JAPAN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 573 JAPAN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 574 JAPAN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 575 JAPAN, BY GENDER, 2018-2025 (USD MILLION)
TABLE 576 JAPAN, BY GENDER, 2026-2033 (USD MILLION)
TABLE 577 JAPAN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 578 JAPAN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 579 JAPAN, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 580 JAPAN, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 581 JAPAN, BY END USER, 2018-2025 (USD MILLION)
TABLE 582 JAPAN, BY END USER, 2026-2033 (USD MILLION)
TABLE 583 JAPAN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 584 JAPAN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 585 CHINA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 586 CHINA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 587 CHINA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 588 CHINA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 589 CHINA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 590 CHINA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 591 CHINA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 592 CHINA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 593 CHINA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 594 CHINA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 595 CHINA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 596 CHINA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 597 CHINA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 598 CHINA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 599 CHINA, BY END USER, 2018-2025 (USD MILLION)
TABLE 600 CHINA, BY END USER, 2026-2033 (USD MILLION)
TABLE 601 CHINA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 602 CHINA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 603 SOUTH KOREA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 604 SOUTH KOREA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 605 SOUTH KOREA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 606 SOUTH KOREA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 607 SOUTH KOREA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 608 SOUTH KOREA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 609 SOUTH KOREA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 610 SOUTH KOREA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 611 SOUTH KOREA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 612 SOUTH KOREA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 613 SOUTH KOREA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 614 SOUTH KOREA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 615 SOUTH KOREA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 616 SOUTH KOREA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 617 SOUTH KOREA, BY END USER, 2018-2025 (USD MILLION)
TABLE 618 SOUTH KOREA, BY END USER, 2026-2033 (USD MILLION)
TABLE 619 SOUTH KOREA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 620 SOUTH KOREA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 621 INDIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 622 INDIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 623 INDIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 624 INDIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 625 INDIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 626 INDIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 627 INDIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 628 INDIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 629 INDIA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 630 INDIA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 631 INDIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 632 INDIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 633 INDIA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 634 INDIA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 635 INDIA, BY END USER, 2018-2025 (USD MILLION)
TABLE 636 INDIA, BY END USER, 2026-2033 (USD MILLION)
TABLE 637 INDIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 638 INDIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 639 SINGAPORE, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 640 SINGAPORE, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 641 SINGAPORE, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 642 SINGAPORE, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 643 SINGAPORE, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 644 SINGAPORE, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 645 SINGAPORE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 646 SINGAPORE, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 647 SINGAPORE, BY GENDER, 2018-2025 (USD MILLION)
TABLE 648 SINGAPORE, BY GENDER, 2026-2033 (USD MILLION)
TABLE 649 SINGAPORE, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 650 SINGAPORE, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 651 SINGAPORE, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 652 SINGAPORE, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 653 SINGAPORE, BY END USER, 2018-2025 (USD MILLION)
TABLE 654 SINGAPORE, BY END USER, 2026-2033 (USD MILLION)
TABLE 655 SINGAPORE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 656 SINGAPORE, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 657 THAILAND, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 658 THAILAND, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 659 THAILAND, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 660 THAILAND, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 661 THAILAND, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 662 THAILAND, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 663 THAILAND, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 664 THAILAND, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 665 THAILAND, BY GENDER, 2018-2025 (USD MILLION)
TABLE 666 THAILAND, BY GENDER, 2026-2033 (USD MILLION)
TABLE 667 THAILAND, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 668 THAILAND, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 669 THAILAND, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 670 THAILAND, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 671 THAILAND, BY END USER, 2018-2025 (USD MILLION)
TABLE 672 THAILAND, BY END USER, 2026-2033 (USD MILLION)
TABLE 673 THAILAND, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 674 THAILAND, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 675 INDONESIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 676 INDONESIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 677 INDONESIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 678 INDONESIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 679 INDONESIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 680 INDONESIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 681 INDONESIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 682 INDONESIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 683 INDONESIA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 684 INDONESIA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 685 INDONESIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 686 INDONESIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 687 INDONESIA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 688 INDONESIA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 689 INDONESIA, BY END USER, 2018-2025 (USD MILLION)
TABLE 690 INDONESIA, BY END USER, 2026-2033 (USD MILLION)
TABLE 691 INDONESIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 692 INDONESIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 693 MALAYSIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 694 MALAYSIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 695 MALAYSIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 696 MALAYSIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 697 MALAYSIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 698 MALAYSIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 699 MALAYSIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 700 MALAYSIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 701 MALAYSIA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 702 MALAYSIA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 703 MALAYSIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 704 MALAYSIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 705 MALAYSIA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 706 MALAYSIA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 707 MALAYSIA, BY END USER, 2018-2025 (USD MILLION)
TABLE 708 MALAYSIA, BY END USER, 2026-2033 (USD MILLION)
TABLE 709 MALAYSIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 710 MALAYSIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 711 PHILIPPINES, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 712 PHILIPPINES, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 713 PHILIPPINES, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 714 PHILIPPINES, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 715 PHILIPPINES, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 716 PHILIPPINES, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 717 PHILIPPINES, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 718 PHILIPPINES, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 719 PHILIPPINES, BY GENDER, 2018-2025 (USD MILLION)
TABLE 720 PHILIPPINES, BY GENDER, 2026-2033 (USD MILLION)
TABLE 721 PHILIPPINES, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 722 PHILIPPINES, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 723 PHILIPPINES, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 724 PHILIPPINES, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 725 PHILIPPINES, BY END USER, 2018-2025 (USD MILLION)
TABLE 726 PHILIPPINES, BY END USER, 2026-2033 (USD MILLION)
TABLE 727 PHILIPPINES, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 728 PHILIPPINES, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 729 AUSTRALIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 730 AUSTRALIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 731 AUSTRALIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 732 AUSTRALIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 733 AUSTRALIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 734 AUSTRALIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 735 AUSTRALIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 736 AUSTRALIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 737 AUSTRALIA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 738 AUSTRALIA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 739 AUSTRALIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 740 AUSTRALIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 741 AUSTRALIA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 742 AUSTRALIA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 743 AUSTRALIA, BY END USER, 2018-2025 (USD MILLION)
TABLE 744 AUSTRALIA, BY END USER, 2026-2033 (USD MILLION)
TABLE 745 AUSTRALIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 746 AUSTRALIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 747 NEW ZEALAND, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 748 NEW ZEALAND, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 749 NEW ZEALAND, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 750 NEW ZEALAND, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 751 NEW ZEALAND, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 752 NEW ZEALAND, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 753 NEW ZEALAND, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 754 NEW ZEALAND, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 755 NEW ZEALAND, BY GENDER, 2018-2025 (USD MILLION)
TABLE 756 NEW ZEALAND, BY GENDER, 2026-2033 (USD MILLION)
TABLE 757 NEW ZEALAND, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 758 NEW ZEALAND, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 759 NEW ZEALAND, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 760 NEW ZEALAND, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 761 NEW ZEALAND, BY END USER, 2018-2025 (USD MILLION)
TABLE 762 NEW ZEALAND, BY END USER, 2026-2033 (USD MILLION)
TABLE 763 NEW ZEALAND, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 764 NEW ZEALAND, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 765 HONG KONG, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 766 HONG KONG, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 767 HONG KONG, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 768 HONG KONG, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 769 HONG KONG, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 770 HONG KONG, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 771 HONG KONG, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 772 HONG KONG, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 773 HONG KONG, BY GENDER, 2018-2025 (USD MILLION)
TABLE 774 HONG KONG, BY GENDER, 2026-2033 (USD MILLION)
TABLE 775 HONG KONG, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 776 HONG KONG, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 777 HONG KONG, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 778 HONG KONG, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 779 HONG KONG, BY END USER, 2018-2025 (USD MILLION)
TABLE 780 HONG KONG, BY END USER, 2026-2033 (USD MILLION)
TABLE 781 HONG KONG, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 782 HONG KONG, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 783 TAIWAN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 784 TAIWAN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 785 TAIWAN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 786 TAIWAN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 787 TAIWAN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 788 TAIWAN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 789 TAIWAN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 790 TAIWAN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 791 TAIWAN, BY GENDER, 2018-2025 (USD MILLION)
TABLE 792 TAIWAN, BY GENDER, 2026-2033 (USD MILLION)
TABLE 793 TAIWAN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 794 TAIWAN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 795 TAIWAN, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 796 TAIWAN, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 797 TAIWAN, BY END USER, 2018-2025 (USD MILLION)
TABLE 798 TAIWAN, BY END USER, 2026-2033 (USD MILLION)
TABLE 799 TAIWAN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 800 TAIWAN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 801 REST OF ASIA-PACIFIC, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 802 REST OF ASIA-PACIFIC, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 803 REST OF ASIA-PACIFIC, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 804 REST OF ASIA-PACIFIC, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 805 REST OF ASIA-PACIFIC, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 806 REST OF ASIA-PACIFIC, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 807 REST OF ASIA-PACIFIC, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 808 REST OF ASIA-PACIFIC, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 809 REST OF ASIA-PACIFIC, BY GENDER, 2018-2025 (USD MILLION)
TABLE 810 REST OF ASIA-PACIFIC, BY GENDER, 2026-2033 (USD MILLION)
TABLE 811 REST OF ASIA-PACIFIC, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 812 REST OF ASIA-PACIFIC, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 813 REST OF ASIA-PACIFIC, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 814 REST OF ASIA-PACIFIC, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 815 REST OF ASIA-PACIFIC, BY END USER, 2018-2025 (USD MILLION)
TABLE 816 REST OF ASIA-PACIFIC, BY END USER, 2026-2033 (USD MILLION)
TABLE 817 REST OF ASIA-PACIFIC, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 818 REST OF ASIA-PACIFIC, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 819 SOUTH AMERICA, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 820 SOUTH AMERICA, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 821 SOUTH AMERICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 822 SOUTH AMERICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 823 SOUTH AMERICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 824 SOUTH AMERICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 825 SOUTH AMERICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 826 SOUTH AMERICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 827 SOUTH AMERICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 828 SOUTH AMERICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 829 SOUTH AMERICA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 830 SOUTH AMERICA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 831 SOUTH AMERICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 832 SOUTH AMERICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 833 SOUTH AMERICA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 834 SOUTH AMERICA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 835 SOUTH AMERICA, BY END USER, 2018-2025 (USD MILLION)
TABLE 836 SOUTH AMERICA, BY END USER, 2026-2033 (USD MILLION)
TABLE 837 SOUTH AMERICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 838 SOUTH AMERICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 839 ARGENTINA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 840 ARGENTINA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 841 ARGENTINA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 842 ARGENTINA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 843 ARGENTINA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 844 ARGENTINA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 845 ARGENTINA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 846 ARGENTINA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 847 ARGENTINA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 848 ARGENTINA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 849 ARGENTINA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 850 ARGENTINA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 851 ARGENTINA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 852 ARGENTINA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 853 ARGENTINA, BY END USER, 2018-2025 (USD MILLION)
TABLE 854 ARGENTINA, BY END USER, 2026-2033 (USD MILLION)
TABLE 855 ARGENTINA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 856 ARGENTINA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 857 BOLIVIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 858 BOLIVIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 859 BOLIVIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 860 BOLIVIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 861 BOLIVIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 862 BOLIVIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 863 BOLIVIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 864 BOLIVIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 865 BOLIVIA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 866 BOLIVIA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 867 BOLIVIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 868 BOLIVIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 869 BOLIVIA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 870 BOLIVIA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 871 BOLIVIA, BY END USER, 2018-2025 (USD MILLION)
TABLE 872 BOLIVIA, BY END USER, 2026-2033 (USD MILLION)
TABLE 873 BOLIVIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 874 BOLIVIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 875 BRAZIL, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 876 BRAZIL, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 877 BRAZIL, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 878 BRAZIL, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 879 BRAZIL, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 880 BRAZIL, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 881 BRAZIL, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 882 BRAZIL, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 883 BRAZIL, BY GENDER, 2018-2025 (USD MILLION)
TABLE 884 BRAZIL, BY GENDER, 2026-2033 (USD MILLION)
TABLE 885 BRAZIL, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 886 BRAZIL, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 887 BRAZIL, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 888 BRAZIL, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 889 BRAZIL, BY END USER, 2018-2025 (USD MILLION)
TABLE 890 BRAZIL, BY END USER, 2026-2033 (USD MILLION)
TABLE 891 BRAZIL, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 892 BRAZIL, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 893 CHILE, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 894 CHILE, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 895 CHILE, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 896 CHILE, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 897 CHILE, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 898 CHILE, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 899 CHILE, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 900 CHILE, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 901 CHILE, BY GENDER, 2018-2025 (USD MILLION)
TABLE 902 CHILE, BY GENDER, 2026-2033 (USD MILLION)
TABLE 903 CHILE, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 904 CHILE, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 905 CHILE, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 906 CHILE, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 907 CHILE, BY END USER, 2018-2025 (USD MILLION)
TABLE 908 CHILE, BY END USER, 2026-2033 (USD MILLION)
TABLE 909 CHILE, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 910 CHILE, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 911 COLOMBIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 912 COLOMBIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 913 COLOMBIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 914 COLOMBIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 915 COLOMBIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 916 COLOMBIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 917 COLOMBIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 918 COLOMBIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 919 COLOMBIA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 920 COLOMBIA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 921 COLOMBIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 922 COLOMBIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 923 COLOMBIA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 924 COLOMBIA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 925 COLOMBIA, BY END USER, 2018-2025 (USD MILLION)
TABLE 926 COLOMBIA, BY END USER, 2026-2033 (USD MILLION)
TABLE 927 COLOMBIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 928 COLOMBIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 929 ECUADOR, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 930 ECUADOR, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 931 ECUADOR, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 932 ECUADOR, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 933 ECUADOR, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 934 ECUADOR, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 935 ECUADOR, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 936 ECUADOR, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 937 ECUADOR, BY GENDER, 2018-2025 (USD MILLION)
TABLE 938 ECUADOR, BY GENDER, 2026-2033 (USD MILLION)
TABLE 939 ECUADOR, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 940 ECUADOR, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 941 ECUADOR, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 942 ECUADOR, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 943 ECUADOR, BY END USER, 2018-2025 (USD MILLION)
TABLE 944 ECUADOR, BY END USER, 2026-2033 (USD MILLION)
TABLE 945 ECUADOR, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 946 ECUADOR, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 947 PARAGUAY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 948 PARAGUAY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 949 PARAGUAY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 950 PARAGUAY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 951 PARAGUAY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 952 PARAGUAY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 953 PARAGUAY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 954 PARAGUAY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 955 PARAGUAY, BY GENDER, 2018-2025 (USD MILLION)
TABLE 956 PARAGUAY, BY GENDER, 2026-2033 (USD MILLION)
TABLE 957 PARAGUAY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 958 PARAGUAY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 959 PARAGUAY, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 960 PARAGUAY, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 961 PARAGUAY, BY END USER, 2018-2025 (USD MILLION)
TABLE 962 PARAGUAY, BY END USER, 2026-2033 (USD MILLION)
TABLE 963 PARAGUAY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 964 PARAGUAY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 965 PERU, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 966 PERU, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 967 PERU, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 968 PERU, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 969 PERU, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 970 PERU, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 971 PERU, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 972 PERU, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 973 PERU, BY GENDER, 2018-2025 (USD MILLION)
TABLE 974 PERU, BY GENDER, 2026-2033 (USD MILLION)
TABLE 975 PERU, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 976 PERU, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 977 PERU, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 978 PERU, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 979 PERU, BY END USER, 2018-2025 (USD MILLION)
TABLE 980 PERU, BY END USER, 2026-2033 (USD MILLION)
TABLE 981 PERU, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 982 PERU, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 983 URUGUAY, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 984 URUGUAY, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 985 URUGUAY, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 986 URUGUAY, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 987 URUGUAY, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 988 URUGUAY, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 989 URUGUAY, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 990 URUGUAY, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 991 URUGUAY, BY GENDER, 2018-2025 (USD MILLION)
TABLE 992 URUGUAY, BY GENDER, 2026-2033 (USD MILLION)
TABLE 993 URUGUAY, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 994 URUGUAY, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 995 URUGUAY, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 996 URUGUAY, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 997 URUGUAY, BY END USER, 2018-2025 (USD MILLION)
TABLE 998 URUGUAY, BY END USER, 2026-2033 (USD MILLION)
TABLE 999 URUGUAY, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1000 URUGUAY, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1001 VENEZUELA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1002 VENEZUELA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1003 VENEZUELA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1004 VENEZUELA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1005 VENEZUELA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1006 VENEZUELA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1007 VENEZUELA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1008 VENEZUELA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1009 VENEZUELA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1010 VENEZUELA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1011 VENEZUELA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1012 VENEZUELA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1013 VENEZUELA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1014 VENEZUELA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1015 VENEZUELA, BY END USER, 2018-2025 (USD MILLION)
TABLE 1016 VENEZUELA, BY END USER, 2026-2033 (USD MILLION)
TABLE 1017 VENEZUELA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1018 VENEZUELA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1019 REST OF SOUTH AMERICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1020 REST OF SOUTH AMERICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1021 REST OF SOUTH AMERICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1022 REST OF SOUTH AMERICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1023 REST OF SOUTH AMERICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1024 REST OF SOUTH AMERICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1025 REST OF SOUTH AMERICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1026 REST OF SOUTH AMERICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1027 REST OF SOUTH AMERICA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1028 REST OF SOUTH AMERICA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1029 REST OF SOUTH AMERICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1030 REST OF SOUTH AMERICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1031 REST OF SOUTH AMERICA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1032 REST OF SOUTH AMERICA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1033 REST OF SOUTH AMERICA, BY END USER, 2018-2025 (USD MILLION)
TABLE 1034 REST OF SOUTH AMERICA, BY END USER, 2026-2033 (USD MILLION)
TABLE 1035 REST OF SOUTH AMERICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1036 REST OF SOUTH AMERICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1037 MIDDLE EAST AND AFRICA, BY COUNTRY, 2018-2025 (USD MILLION)
TABLE 1038 MIDDLE EAST AND AFRICA, BY COUNTRY, 2026-2033 (USD MILLION)
TABLE 1039 MIDDLE EAST AND AFRICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1040 MIDDLE EAST AND AFRICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1041 MIDDLE EAST AND AFRICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1042 MIDDLE EAST AND AFRICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1043 MIDDLE EAST AND AFRICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1044 MIDDLE EAST AND AFRICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1045 EAST AND AFRICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1046 MIDDLE EAST AND AFRICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1047 MIDDLE EAST AND AFRICA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1048 MIDDLE EAST AND AFRICA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1049 MIDDLE EAST AND AFRICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1050 MIDDLE EAST AND AFRICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1051 MIDDLE EAST AND AFRICA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1052 MIDDLE EAST AND AFRICA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1053 MIDDLE EAST AND AFRICA, BY END USER, 2018-2025 (USD MILLION)
TABLE 1054 MIDDLE EAST AND AFRICA, BY END USER, 2026-2033 (USD MILLION)
TABLE 1055 MIDDLE EAST AND AFRICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1056 MIDDLE EAST AND AFRICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1057 SOUTH AFRICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1058 SOUTH AFRICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1059 SOUTH AFRICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1060 SOUTH AFRICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1061 SOUTH AFRICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1062 SOUTH AFRICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1063 SOUTH AFRICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1064 SOUTH AFRICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1065 SOUTH AFRICA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1066 SOUTH AFRICA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1067 SOUTH AFRICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1068 SOUTH AFRICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1069 SOUTH AFRICA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1070 SOUTH AFRICA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1071 SOUTH AFRICA, BY END USER, 2018-2025 (USD MILLION)
TABLE 1072 SOUTH AFRICA, BY END USER, 2026-2033 (USD MILLION)
TABLE 1073 SOUTH AFRICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1074 SOUTH AFRICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1075 EGYPT, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1076 EGYPT, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1077 EGYPT, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1078 EGYPT, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1079 EGYPT, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1080 EGYPT, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1081 EGYPT, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1082 EGYPT, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1083 EGYPT, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1084 EGYPT, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1085 EGYPT, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1086 EGYPT, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1087 EGYPT, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1088 EGYPT, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1089 EGYPT, BY END USER, 2018-2025 (USD MILLION)
TABLE 1090 EGYPT, BY END USER, 2026-2033 (USD MILLION)
TABLE 1091 EGYPT, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1092 EGYPT, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1093 SAUDI ARABIA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1094 SAUDI ARABIA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1095 SAUDI ARABIA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1096 SAUDI ARABIA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1097 SAUDI ARABIA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1098 SAUDI ARABIA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1099 SAUDI ARABIA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1100 SAUDI ARABIA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1101 SAUDI ARABIA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1102 SAUDI ARABIA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1103 SAUDI ARABIA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1104 SAUDI ARABIA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1105 SAUDI ARABIA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1106 SAUDI ARABIA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1107 SAUDI ARABIA, BY END USER, 2018-2025 (USD MILLION)
TABLE 1108 SAUDI ARABIA, BY END USER, 2026-2033 (USD MILLION)
TABLE 1109 SAUDI ARABIA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1110 SAUDI ARABIA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1111 UNITED ARAB EMIRATES, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1112 UNITED ARAB EMIRATES, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1113 UNITED ARAB EMIRATES, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1114 UNITED ARAB EMIRATES, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1115 UNITED ARAB EMIRATES, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1116 UNITED ARAB EMIRATES, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1117 UNITED ARAB EMIRATES, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1118 UNITED ARAB EMIRATES, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1119 UNITED ARAB EMIRATES, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1120 UNITED ARAB EMIRATES, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1121 UNITED ARAB EMIRATES, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1122 UNITED ARAB EMIRATES, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1123 UNITED ARAB EMIRATES, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1124 UNITED ARAB EMIRATES, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1125 UNITED ARAB EMIRATES, BY END USER, 2018-2025 (USD MILLION)
TABLE 1126 UNITED ARAB EMIRATES, BY END USER, 2026-2033 (USD MILLION)
TABLE 1127 UNITED ARAB EMIRATES, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1128 UNITED ARAB EMIRATES, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1129 ISRAEL, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1130 ISRAEL, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1131 ISRAEL, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1132 ISRAEL, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1133 ISRAEL, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1134 ISRAEL, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1135 ISRAEL, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1136 ISRAEL, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1137 ISRAEL, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1138 ISRAEL, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1139 ISRAEL, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1140 ISRAEL, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1141 ISRAEL, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1142 ISRAEL, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1143 ISRAEL, BY END USER, 2018-2025 (USD MILLION)
TABLE 1144 ISRAEL, BY END USER, 2026-2033 (USD MILLION)
TABLE 1145 ISRAEL, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1146 ISRAEL, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1147 BAHRAIN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1148 BAHRAIN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1149 BAHRAIN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1150 BAHRAIN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1151 BAHRAIN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1152 BAHRAIN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1153 BAHRAIN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1154 BAHRAIN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1155 BAHRAIN, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1156 BAHRAIN, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1157 BAHRAIN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1158 BAHRAIN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1159 BAHRAIN, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1160 BAHRAIN, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1161 BAHRAIN, BY END USER, 2018-2025 (USD MILLION)
TABLE 1162 BAHRAIN, BY END USER, 2026-2033 (USD MILLION)
TABLE 1163 BAHRAIN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1164 BAHRAIN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1165 KUWAIT, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1166 KUWAIT, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1167 KUWAIT, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1168 KUWAIT, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1169 KUWAIT, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1170 KUWAIT, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1171 KUWAIT, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1172 KUWAIT, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1173 KUWAIT, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1174 KUWAIT, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1175 KUWAIT, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1176 KUWAIT, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1177 KUWAIT, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1178 KUWAIT, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1179 KUWAIT, BY END USER, 2018-2025 (USD MILLION)
TABLE 1180 KUWAIT, BY END USER, 2026-2033 (USD MILLION)
TABLE 1181 KUWAIT, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1182 KUWAIT, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1183 OMAN, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1184 OMAN, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1185 OMAN, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1186 OMAN, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1187 OMAN, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1188 OMAN, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1189 OMAN, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1190 OMAN, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1191 OMAN, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1192 OMAN, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1193 OMAN, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1194 OMAN, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1195 OMAN, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1196 OMAN, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1197 OMAN, BY END USER, 2018-2025 (USD MILLION)
TABLE 1198 OMAN, BY END USER, 2026-2033 (USD MILLION)
TABLE 1199 OMAN, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1200 OMAN, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1201 QATAR, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1202 QATAR, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1203 QATAR, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1204 QATAR, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1205 QATAR, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1206 QATAR, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1207 QATAR, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1208 QATAR, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1209 QATAR, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1210 QATAR, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1211 QATAR, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1212 QATAR, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1213 QATAR, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1214 QATAR, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1215 QATAR, BY END USER, 2018-2025 (USD MILLION)
TABLE 1216 QATAR, BY END USER, 2026-2033 (USD MILLION)
TABLE 1217 QATAR, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1218 QATAR, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1219 REST OF MIDDLE EAST & AFRICA, BY PRODUCT TYPE, 2018-2025 (USD MILLION)
TABLE 1220 REST OF MIDDLE EAST & AFRICA, BY PRODUCT TYPE, 2026-2033 (USD MILLION)
TABLE 1221 REST OF MIDDLE EAST & AFRICA, BY HORMONAL COMPOSITION, 2018-2025 (USD MILLION)
TABLE 1222 REST OF MIDDLE EAST & AFRICA, BY HORMONAL COMPOSITION, 2026-2033 (USD MILLION)
TABLE 1223 REST OF MIDDLE EAST & AFRICA, BY DURATION OF ACTION, 2018-2025 (USD MILLION)
TABLE 1224 REST OF MIDDLE EAST & AFRICA, BY DURATION OF ACTION, 2026-2033 (USD MILLION)
TABLE 1225 REST OF MIDDLE EAST & AFRICA, BY ROUTE OF ADMINISTRATION, 2018-2025 (USD MILLION)
TABLE 1226 REST OF MIDDLE EAST & AFRICA, BY ROUTE OF ADMINISTRATION, 2026-2033 (USD MILLION)
TABLE 1227 REST OF MIDDLE EAST & AFRICA, BY GENDER, 2018-2025 (USD MILLION)
TABLE 1228 REST OF MIDDLE EAST & AFRICA, BY GENDER, 2026-2033 (USD MILLION)
TABLE 1229 REST OF MIDDLE EAST & AFRICA, BY PRESCRIPTION STATUS, 2018-2025 (USD MILLION)
TABLE 1230 REST OF MIDDLE EAST & AFRICA, BY PRESCRIPTION STATUS, 2026-2033 (USD MILLION)
TABLE 1231 REST OF MIDDLE EAST & AFRICA, BY AGE GROUP, 2018-2025 (USD MILLION)
TABLE 1232 REST OF MIDDLE EAST & AFRICA, BY AGE GROUP, 2026-2033 (USD MILLION)
TABLE 1233 REST OF MIDDLE EAST & AFRICA, BY END USER, 2018-2025 (USD MILLION)
TABLE 1234 REST OF MIDDLE EAST & AFRICA, BY END USER, 2026-2033 (USD MILLION)
TABLE 1235 REST OF MIDDLE EAST & AFRICA, BY DISTRIBUTION CHANNEL, 2018-2025 (USD MILLION)
TABLE 1236 REST OF MIDDLE EAST & AFRICA, BY DISTRIBUTION CHANNEL, 2026-2033 (USD MILLION)
TABLE 1237 GLOBAL CONTRACEPTIVE MARKET: COMPANY SHARE, 2025
TABLE 1238 GLOBAL CONTRACEPTIVE MARKET: MERGERS & ACQUISITIONS
TABLE 1239 GLOBAL CONTRACEPTIVE MARKET: NEW PRODUCT DEVELOPMENT & APPROVALS
TABLE 1240 GLOBAL CONTRACEPTIVE MARKET: EXPANSIONS
TABLE 1241 GLOBAL CONTRACEPTIVE MARKET: PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
TABLE 1242 GLOBAL CONTRACEPTIVE MARKET: STRENGTHS AND WEAKNESSES
TABLE 1243 GLOBAL CONTRACEPTIVE MARKET: OPPORTUNITIES AND THREATS
TABLE 1244 BAYER AG: PRODUCT PORTFOLIO
TABLE 1245 BAYER AG: RECENT DEVELOPMENTS
TABLE 1246 BAYER AG: RECENT NEWS
TABLE 1247 ORGANON & CO.: PRODUCT PORTFOLIO
TABLE 1248 ORGANON & CO.: RECENT DEVELOPMENTS
TABLE 1249 ORGANON & CO.: RECENT NEWS
TABLE 1250 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 1251 TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 1252 TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT NEWS
TABLE 1253 PFIZER INC.: PRODUCT PORTFOLIO
TABLE 1254 PFIZER INC.: RECENT DEVELOPMENTS
TABLE 1255 PFIZER INC.: RECENT NEWS
TABLE 1256 GEDEON RICHTER PLC.: PRODUCT PORTFOLIO
TABLE 1257 GEDEON RICHTER PLC.: RECENT DEVELOPMENTS
TABLE 1258 GEDEON RICHTER PLC.: RECENT NEWS
TABLE 1259 VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 1260 VIATRIS INC.: RECENT DEVELOPMENTS
TABLE 1261 VIATRIS INC.: RECENT NEWS
TABLE 1262 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 1263 SUN PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 1264 SUN PHARMACEUTICAL INDUSTRIES LTD.: RECENT NEWS
TABLE 1265 LUPIN: PRODUCT PORTFOLIO
TABLE 1266 LUPIN: RECENT DEVELOPMENTS
TABLE 1267 LUPIN: RECENT NEWS
TABLE 1268 GLENMARK PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 1269 GLENMARK PHARMACEUTICALS: RECENT DEVELOPMENTS
TABLE 1270 GLENMARK PHARMACEUTICALS: RECENT NEWS
TABLE 1271 CIPLA: PRODUCT PORTFOLIO
TABLE 1272 CIPLA: RECENT DEVELOPMENTS
TABLE 1273 CIPLA: RECENT NEWS
TABLE 1274 APOTEX INC.: PRODUCT PORTFOLIO
TABLE 1275 APOTEX INC.: RECENT DEVELOPMENTS
TABLE 1276 APOTEX INC.: RECENT NEWS
TABLE 1277 INSUD PHARMA, S.L.: PRODUCT PORTFOLIO
TABLE 1278 INSUD PHARMA, S.L.: RECENT DEVELOPMENTS
TABLE 1279 INSUD PHARMA, S.L.: RECENT NEWS
TABLE 1280 COOPERSURGICAL, INC.: PRODUCT PORTFOLIO
TABLE 1281 COOPERSURGICAL, INC.: RECENT DEVELOPMENTS
TABLE 1282 COOPERSURGICAL, INC.: RECENT NEWS
TABLE 1283 MANKIND: PRODUCT PORTFOLIO
TABLE 1284 MANKIND: RECENT DEVELOPMENTS
TABLE 1285 MANKIND: RECENT NEWS
TABLE 1286 CHURCH & DWIGHT CO., INC.: PRODUCT PORTFOLIO
TABLE 1287 CHURCH & DWIGHT CO., INC.: RECENT DEVELOPMENTS
TABLE 1288 CHURCH & DWIGHT CO., INC.: RECENT NEWS
TABLE 1289 RECKITT: PRODUCT PORTFOLIO
TABLE 1290 RECKITT: RECENT DEVELOPMENTS
TABLE 1291 RECKITT: RECENT NEWS
TABLE 1292 OKAMOTO INDUSTRIES, INC.: PRODUCT PORTFOLIO
TABLE 1293 OKAMOTO INDUSTRIES, INC.: RECENT DEVELOPMENTS
TABLE 1294 OKAMOTO INDUSTRIES, INC.: RECENT NEWS
TABLE 1295 SAGAMI RUBBER INDUSTRIES CO., LTD.: PRODUCT PORTFOLIO
TABLE 1296 SAGAMI RUBBER INDUSTRIES CO., LTD.: RECENT DEVELOPMENTS
TABLE 1297 SAGAMI RUBBER INDUSTRIES CO., LTD.: RECENT NEWS
TABLE 1298 FUJI LATEX CO., LTD.: PRODUCT PORTFOLIO
TABLE 1299 FUJI LATEX CO., LTD.: RECENT DEVELOPMENTS
TABLE 1300 FUJI LATEX CO., LTD.: RECENT NEWS
TABLE 1301 KAREX BERHAD: PRODUCT PORTFOLIO
TABLE 1302 KAREX BERHAD: RECENT DEVELOPMENTS
TABLE 1303 KAREX BERHAD: RECENT NEWS
TABLE 1304 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 1305 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED: RECENT DEVELOPMENTS
TABLE 1306 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED: RECENT NEWS
TABLE 1307 MAYER LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 1308 MAYER LABORATORIES, INC.: RECENT DEVELOPMENTS
TABLE 1309 MAYER LABORATORIES, INC.: RECENT NEWS
TABLE 1310 CUPID: PRODUCT PORTFOLIO
TABLE 1311 CUPID: RECENT DEVELOPMENTS
TABLE 1312 CUPID: RECENT NEWS
TABLE 1313 TTK: PRODUCT PORTFOLIO
TABLE 1314 TTK: RECENT DEVELOPMENTS
TABLE 1315 TTK: RECENT NEWS
TABLE 1316 PREGNA INTERNATIONAL LIMITED: PRODUCT PORTFOLIO
TABLE 1317 PREGNA INTERNATIONAL LIMITED: RECENT DEVELOPMENTS
TABLE 1318 PREGNA INTERNATIONAL LIMITED: RECENT NEWS
TABLE 1319 SMB CORPORATION OF INDIA: PRODUCT PORTFOLIO
TABLE 1320 SMB CORPORATION OF INDIA: RECENT DEVELOPMENTS
TABLE 1321 SMB CORPORATION OF INDIA: RECENT NEWS
TABLE 1322 EUROGINE: PRODUCT PORTFOLIO
TABLE 1323 EUROGINE: RECENT DEVELOPMENTS
TABLE 1324 EUROGINE: RECENT NEWS
TABLE 1325 OCON MEDICAL LTD.: PRODUCT PORTFOLIO
TABLE 1326 OCON MEDICAL LTD.: RECENT DEVELOPMENTS
TABLE 1327 OCON MEDICAL LTD.: RECENT NEWS
TABLE 1328 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 1329 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS
TABLE 1330 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD.: RECENT NEWS
TABLE 1331 HLL LIFECARE LIMITED: PRODUCT PORTFOLIO
TABLE 1332 HLL LIFECARE LIMITED: RECENT DEVELOPMENTS
TABLE 1333 HLL LIFECARE LIMITED: RECENT NEWS
List of Figure
FIGURE 1 GLOBAL CONTRACEPTIVE MARKET: SEGMENTATION
FIGURE 2 MARKET COVERAGE GRID: ROUTES TO MARKET EVIDENCED IN PUBLISHED SOURCES
FIGURE 3 GLOBAL CONTRACEPTIVE MARKET, 2018-2033 (USD MILLION)
FIGURE 4 GLOBAL CONTRACEPTIVE MARKET: SEGMENTATION AT A GLANCE, 2025
FIGURE 5 GLOBAL CONTRACEPTIVE MARKET: KEY FINDINGS
FIGURE 6 GLOBAL CONTRACEPTIVE MARKET: DRIVERS IMPACT RADAR
FIGURE 7 GLOBAL CONTRACEPTIVE MARKET: PORTER'S FIVE FORCES
FIGURE 8 GLOBAL CONTRACEPTIVE MARKET: PESTLE ANALYSIS
FIGURE 9 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE: KEY FINDINGS
FIGURE 10 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2025
FIGURE 11 GLOBAL CONTRACEPTIVE MARKET, BY PRODUCT TYPE, 2033 (USD MILLION)
FIGURE 12 GLOBAL CONTRACEPTIVE MARKET, BY HORMONAL COMPOSITION: KEY FINDINGS
FIGURE 13 GLOBAL CONTRACEPTIVE MARKET, BY HORMONAL COMPOSITION, 2025
FIGURE 14 GLOBAL CONTRACEPTIVE MARKET, BY DURATION OF ACTION: KEY FINDINGS
FIGURE 15 GLOBAL CONTRACEPTIVE MARKET, BY DURATION OF ACTION, 2025
FIGURE 16 GLOBAL CONTRACEPTIVE MARKET, BY ROUTE OF ADMINISTRATION: KEY FINDINGS
FIGURE 17 GLOBAL CONTRACEPTIVE MARKET, BY ROUTE OF ADMINISTRATION, 2025
FIGURE 18 GLOBAL CONTRACEPTIVE MARKET, BY GENDER: KEY FINDINGS
FIGURE 19 GLOBAL CONTRACEPTIVE MARKET, BY GENDER, 2025
FIGURE 20 GLOBAL CONTRACEPTIVE MARKET, BY PRESCRIPTION STATUS: KEY FINDINGS
FIGURE 21 GLOBAL CONTRACEPTIVE MARKET, BY PRESCRIPTION STATUS, 2025
FIGURE 22 GLOBAL CONTRACEPTIVE MARKET, BY AGE GROUP: KEY FINDINGS
FIGURE 23 GLOBAL CONTRACEPTIVE MARKET, BY AGE GROUP, 2025
FIGURE 24 GLOBAL CONTRACEPTIVE MARKET, BY END USER: KEY FINDINGS
FIGURE 25 GLOBAL CONTRACEPTIVE MARKET, BY END USER, 2025
FIGURE 26 GLOBAL CONTRACEPTIVE MARKET, BY DISTRIBUTION CHANNEL: KEY FINDINGS
FIGURE 27 GLOBAL CONTRACEPTIVE MARKET, BY DISTRIBUTION CHANNEL, 2025
FIGURE 28 GLOBAL CONTRACEPTIVE MARKET, BY REGION: KEY FINDINGS
FIGURE 29 GLOBAL CONTRACEPTIVE MARKET, BY REGION, 2025
FIGURE 30 NORTH AMERICA, BY COUNTRY, 2025
FIGURE 31 EUROPE, BY COUNTRY, 2025
FIGURE 32 ASIA PACIFIC, BY COUNTRY, 2025
FIGURE 33 SOUTH AMERICA, BY COUNTRY, 2025
FIGURE 34 MIDDLE EAST AND AFRICA, BY COUNTRY, 2025
FIGURE 35 ESTIMATED COMPANY SHARE, GLOBAL CONTRACEPTIVE, 2025 (%)
FIGURE 36 GLOBAL CONTRACEPTIVE: SWOT ANALYSIS
FIGURE 37 BAYER AG, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 38 BAYER AG: COMPANY SNAPSHOT
FIGURE 39 ORGANON & CO., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 40 ORGANON & CO.: COMPANY SNAPSHOT
FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
FIGURE 43 PFIZER INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 44 PFIZER INC.: COMPANY SNAPSHOT
FIGURE 45 GEDEON RICHTER PLC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 46 GEDEON RICHTER PLC.: COMPANY SNAPSHOT
FIGURE 47 VIATRIS INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 48 VIATRIS INC.: COMPANY SNAPSHOT
FIGURE 49 SUN PHARMACEUTICAL INDUSTRIES LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 50 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
FIGURE 51 LUPIN, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 52 LUPIN: COMPANY SNAPSHOT
FIGURE 53 GLENMARK PHARMACEUTICALS, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 54 GLENMARK PHARMACEUTICALS: COMPANY SNAPSHOT
FIGURE 55 CIPLA, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 56 CIPLA: COMPANY SNAPSHOT
FIGURE 57 APOTEX INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 58 APOTEX INC.: COMPANY SNAPSHOT
FIGURE 59 INSUD PHARMA, S.L., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 60 INSUD PHARMA, S.L.: COMPANY SNAPSHOT
FIGURE 61 COOPERSURGICAL, INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 62 COOPERSURGICAL, INC.: COMPANY SNAPSHOT
FIGURE 63 MANKIND, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 64 MANKIND: COMPANY SNAPSHOT
FIGURE 65 CHURCH & DWIGHT CO., INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 66 CHURCH & DWIGHT CO., INC.: COMPANY SNAPSHOT
FIGURE 67 RECKITT, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 68 RECKITT: COMPANY SNAPSHOT
FIGURE 69 OKAMOTO INDUSTRIES, INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 70 OKAMOTO INDUSTRIES, INC.: COMPANY SNAPSHOT
FIGURE 71 SAGAMI RUBBER INDUSTRIES CO., LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 72 SAGAMI RUBBER INDUSTRIES CO., LTD.: COMPANY SNAPSHOT
FIGURE 73 FUJI LATEX CO., LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 74 FUJI LATEX CO., LTD.: COMPANY SNAPSHOT
FIGURE 75 KAREX BERHAD, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 76 KAREX BERHAD: COMPANY SNAPSHOT
FIGURE 77 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 78 THAI NIPPON RUBBER INDUSTRY PUBLIC COMPANY LIMITED: COMPANY SNAPSHOT
FIGURE 79 MAYER LABORATORIES, INC., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 80 MAYER LABORATORIES, INC.: COMPANY SNAPSHOT
FIGURE 81 CUPID, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 82 CUPID: COMPANY SNAPSHOT
FIGURE 83 TTK, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 84 TTK: COMPANY SNAPSHOT
FIGURE 85 PREGNA INTERNATIONAL LIMITED, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 86 PREGNA INTERNATIONAL LIMITED: COMPANY SNAPSHOT
FIGURE 87 SMB CORPORATION OF INDIA, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 88 SMB CORPORATION OF INDIA: COMPANY SNAPSHOT
FIGURE 89 EUROGINE, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 90 EUROGINE: COMPANY SNAPSHOT
FIGURE 91 OCON MEDICAL LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 92 OCON MEDICAL LTD.: COMPANY SNAPSHOT
FIGURE 93 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD., SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 94 SHANGHAI DAHUA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
FIGURE 95 HLL LIFECARE LIMITED, SHARE OF THE GLOBAL CONTRACEPTIVE MARKET, 2025
FIGURE 96 HLL LIFECARE LIMITED: COMPANY SNAPSHOT
